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Bibliographische Beschreibung 
Dukart, Jürgen 
Contribution of FDG-PET and MRI to improve Understanding, Detection and Differentiation of 
Dementia 
Universität Leipzig, Dissertation 
77 S. ¹, 100 Lit. ², 9 Abb., 8 Tab., 0 Anlagen  
Referat: 
The present work deals on the one hand with evaluation of methodical aspect of intensity 
normalization in preprocessing of [F18]fluorodeoxyglucose positron emission tomography (FDG-
PET). On the other hand, in this work FDG-PET and magnetic resonance imaging (MRI) 
information are co-evaluated to improve understanding and diagnostic accuracy of Alzheimer’s 
disease (AD) and frontotemporal lobar degeneration (FTLD). Differences between both types of 
dementia patients and control subjects were assessed in both imaging modalities using voxel-
based morphometry. Additionally, both imaging modalities were systematically compared 
regarding their contribution for detection and differentiation of both types of dementia using 
support vector machine classification. Thereby, FDG-PET and MRI whole-brain and region-of-
interest information were used separately and by combining them to investigate which method 
provides the highest diagnostic accuracy for both, detection and differentiation of AD and FTLD 
The comparison of two reference regions for intensity normalization in FDG-PET, cerebellar and 
global intensity mean, revealed a remarkable differential effect of both intensity normalization 
procedures for detection and differentiation of dementia. While the cerebellar normalization was 
superior for differentiation between dementia patients and control subjects and therefore for 
detection of dementia, there was an opposite effect for differentiation of AD and FTLD. For this 
comparison global normalization was highly superior in detecting group differences.  
Voxel-based morphometry resulted in a differential pattern of atrophy and hypometabolism in 
AD and FTLD patients, indicating different proceeding of both disorders and providing support 
for the assumption of different underlying mechanisms in AD and FTLD.Additionally, applying 
support vector machine classification on combined information from FDG-PET and MRI 
provided highest accuracy rates for both, detection and differentiation of AD and FTLD. This 
result for differentiation of AD patients and control subjects was also validated using a 
multicenter dataset.  
The results of this study emphasize the importance of combined use and evaluation of FDG-
PET and MRI to improve understanding and diagnostic accuracy of dementia. 
¹ Seitenzahl insgesamt 
² Zahl der im Literaturverzeichnis ausgewiesenen Literaturangaben 
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1. General introduction 
 
Dementia has become a major problem in our society with an estimated 1.07 million people in 
Germany suffering from a moderate to severe form of dementia in 2007 and an actual rate of 
244000 new cases per year (Ziegler and Doblhammer, 2009). Considering the increases in life 
expectancy and the accompanying trend of low birth rates in Western society in recent decades 
the proportion of people suffering from dementia is expected to increase further in coming 
decades. Worldwide, the absolute number of dementia patients is expected to increase from 25 
million in 2000 to 114 million in 2050 (Wimo et al., 2003). In 2001 costs of dementia were 
already estimated to make up 12% of the total global cost of illness (World Health Organization, 
2001). To address this considerable problem arising in our society, substantial progress is 
required in medical research regarding diagnostic accuracy, understanding of neural 
mechanisms and treatment of different dementia disorders. Although progress has been made 
in all of these research areas in recent decades, there is still a great deal of improvement 
needed to address the growing problematic of dementia in our society.  
The most common type of dementia is Alzheimer’s disease (AD), with a total of about 60% of 
dementia patients receiving the diagnosis of this specific neurodegenerative disorder (Fratiglioni 
et al., 1999). Recently, revised diagnostic criteria for AD (Dubois et al., 2007) suggested the 
following core features for the clinical diagnosis of probable AD: gradual and progressive 
change in memory function reported by patients or informants over more than 6 months and 
objective evidence of significantly impaired episodic memory on testing, which can be isolated 
or associated with other cognitive changes. 
A less common, although still very frequent neurodegenerative disorder, is frontotemporal lobar 
degeneration (FTLD). Estimates of the prevalence of FTLD vary greatly, with an overall 
prevalence of between 3.6 and 15 patients per 100000 in the 45- to 64-year age groups 
(Ratnavalli et al., 2002; Rosso et al., 2003). The results of these studies suggest that FTLD is 
the second most common diagnosis of dementia in individuals younger than 65. In the cohort of 
85 years old, an even higher prevalence of 3% for patients with a subtype of FTLD has been 
reported in the total population (Gislason et al., 2003).  
Due to the inhomogeneous pattern of cognitive impairment in FTLD, it has been suggested to 
divide FTLD into three major groups: frontotemporal dementia, semantic dementia and 
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progressive non-fluent aphasia (Neary et al., 1998). Frontotemporal dementia is characterized 
by alterations in behavior and personality, namely decline in social interpersonal conduct, 
impairment in regulation of personal conduct, emotional blunting, and loss of insight. Semantic 
dementia is described as a language disorder characterized by the following: empty fluent 
speech, loss of word meaning, or semantic paraphasias, a perceptual disorder characterized by 
impaired recognition of familiar faces or object identity, preserved perceptual matching and 
drawing reproduction, preserved single-word repetition, and preserved ability to read aloud and 
write to dictation orthographically regular words. Specific for progressive non-fluent aphasia is 
non-fluent spontaneous speech with at least one of the following symptoms: agrammatism, 
phonemic paraphasias, or anomia. Specific neural networks have been reported for each of the 
three clinically defined subtypes of FTLD (Schroeter et al., 2007).   
The treatment of dementia syndromes is still an unsolved problem. Effective drugs have been 
reported in recent literature, which slow down or even briefly improve cognitive decline in AD 
(Wilcock et al., 2000; Doody et al., 2001; Hansen et al., 2008) or behavioral symptoms in FTLD 
(Ikeda et al., 2004). Although, there is still no efficient treatment providing either recovery of the 
effects of proceeding neurodegeneration or even a permanent stop in cognitive decline, a lot of 
research is currently directed to development of such therapeutic approaches. For this reason, it 
is highly important to provide accurate methods enabling early detection and differentiation of 
neurodegenerative disorders, as these are a prerequisite for an early and successful treatment. 
 
1.1. Diagnostic accuracy of Alzheimer’s disease and frontotemporal lobar degeneration 

To improve the correct evaluation of a specific treatment, it is also necessary to improve 
diagnostic accuracy of specific dementia types. An initially incorrect group selection would 
substantially lower the efficacy estimation of a specific therapeutic approach. Furthermore, the 
correct diagnostic classification of individual cases is highly relevant for the application of the 
correct therapeutic treatment if this is available. For dementia syndromes, diagnostic accuracy 
is difficult to assess even in studies using autopsy confirmed data, given that the 
neuropathological standard is not the same in all studies. Another difficulty with using 
neuropathology as a “gold standard” for estimation of diagnostic accuracy is that healthy 
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subjects sometimes show similar neuropathological changes to those of AD patients (Braak and 
Braak, 1991). Moreover, it is well known that, in FTLD, histological changes are nonspecific. 
Any of the histological subtypes can be associated with the three clinical subtypes of FTLD 
(Hodges et al., 2004, Whitwell et al., 2005). 
Studies assessing the diagnostic accuracy of AD based on clinical criteria (e.g., NINCDS-
ARDRA criteria [National Institute of Neurological and Communication Disorders and Stroke–
Alzheimer's disease and Related Disorders Association]: McKhann et al., 1984) reported 
accuracy rates between 65 and 100% for detection of this specific dementia syndrome (Klatka 
et al., 1996; Petrovitch et al., 2001; Rascovsky et al., 2002). However, for AD, a high 
discrepancy was observed between sensitivity and specificity with a substantially higher 
sensitivity compared to specificity (Varma et al., 1999; Jagust et al., 2007). For FTLD, reported 
diagnostic accuracies based on clinical criteria ranged between 17 and 85% (Rascovsky et al., 
2002; Knopman et al., 2005; Mendez et al., 2007). In comparison to AD syndrome, the opposite 
pattern between sensitivity and specificity has been reported for FTLD, with much higher 
specificity compared to sensitivity rates. Sensitivity ranged between 36.5 and 79% while 
specificity was up to 100% (Knopman et al., 2005; Mendez et al., 2007). For both types of 
dementia, diagnostic accuracies for early detection and differentiation with other dementia 
syndromes are still in need of improvement. 
 
1.2. Biomarkers in dementia 
 
Earlier diagnostic criteria for AD and FTLD have mainly relied on clinical and 
neuropsychological symptoms (McKhann et al., 1984; The Lund and Manchester Groups, 1994; 
Neary et al., 1998). However, recent studies reported substantial imaging abnormalities for both 
groups of dementia patients in different imaging modalities. Abnormal patterns in dementia 
patients have been observed using positron emission tomography (PET) with different ligands, 
magnetic resonance imaging (MRI) and single photon emission computed tomography (Rosen 
et al., 2002; Ishii et al., 2005; Nestor et al., 2005; Desgranges et al., 2007; Clark et al., 2008; 
Habeck et al., 2008; Jack et al., 2008). Accordingly, it has been suggested to integrate imaging 
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markers into diagnostic criteria for specific dementia syndromes (Dubois et al., 2007; Clark et al., 
2008; Kipps et al., 2009).  
Different methods have been proposed for the integration of such biomarkers into the diagnostic 
procedure ranging from basic evaluation of such images by radiologists, semiautomatic 
evaluation by combining automatic feature selection and evaluation by physicians, to fully 
automatic univariate and multivariate approaches (Hoffman et al., 2000; Santens et al., 2001, 
Mosconi et al., 2006; Fung and Stoeckel, 2007; Habeck et al., 2008; Klöppel et al., 2008a, b; 
Habert et al., 2009). The integration of such biomarkers has been shown to substantially 
improve diagnostic accuracy of dementia syndromes, with accuracy rates of above 90% for 
detection (Fung and Stoeckel, 2007; Matsunari et al., 2007; Davatzikos et al., 2008; Klöppel et 
al., 2008a, b) and between 84 and 89% for differentiation of AD and FTLD (Davatzikos et al., 
2008; Klöppel et al., 2008a; Horn et al., 2009). Furthermore, studies comparing evaluation by 
physicians with multivariate approaches revealed the superiority of the multivariate methods for 
detection and differentiation of dementia syndromes (Klöppel et al., 2008b; Horn et al., 2009). 
Evaluation of different imaging markers in neurodegenerative disorders not only provides a 
good instrument to improve diagnostic accuracy of those. Additionally, biomarkers might provide 
a new way to improve understanding of the underlying processes in different dementia 
syndromes and so effectively contribute to the development of new treatment alternatives. 
Different imaging markers provide different information regarding neural changes in 
neurodegenerative disorders. For example, in AD, changes in measurements provided by 
[F18]fluorodeoxyglucose PET (FDG-PET) have been shown to precede or at least to have a 
faster progression in some specific regions than those measured by structural MRI suggesting a 
mechanism of functional disruption in early AD ahead of actual atrophy (Chetelat et al., 2008).  
A further – up to now rather theoretical – application of biomarkers for the treatment of 
neurodegenerative disorders might be their use for the evaluation of the efficacy of a specific 
therapeutic approach. Assessment of reduction of glucose hypometabolism in AD or FTLD 
could, for example, provide a measurement of recovery of functional activity in these disorders.  
However, for the optimal use of biomarkers to improve understanding, detection and 
differentiation of dementia syndromes, specific methodical questions still have to be solved. 
Such questions range from optimization of preprocessing algorithms to enhance statistical 
evaluation of a specific imaging modality to an improvement of algorithms for the combination of 
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different imaging modalities. Addressing such questions is necessary to enable valid 
interpretation of imaging findings. Further methodical questions concern the optimal use of 
observed imaging abnormalities to increase diagnostic accuracy of specific dementia 
syndromes. The present work deals with such questions of optimizing preprocessing, and the 
combination and application of FDG-PET and MRI to improve understanding and diagnostic 
accuracy of AD and FTLD. Algorithms developed in this study are applied to different datasets 
of patients with AD, FTLD and to data of control subjects. The results obtained for the 
optimization of specific preprocessing steps, for the combined use of FDG-PET and MRI, and 
for the validation of the diagnostic procedure developed are discussed as separate studies in 
different chapters.  
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2. Intensity normalization in [F18]fluorodeoxyglucose positron emission tomography 
 
The following section deals with optimization of specific methodical aspects in preprocessing of 
FDG-PET to enable an accurate univariate and multivariate statistical evaluation. The 
clarification and optimization of these methodical aspects is important to enable an optimal 
qualitative and quantitative evaluation of FDG-PET to improve understanding, detection and 
differentiation of AD and FTLD. To enable this statistical evaluation of imaging data across 
different subjects, complex preprocessing algorithms are applied to normalize individual imaging 
data to a common space and to a common scale so trying to overcome differences in the 
interindividual anatomy and in the acquisition of the data. An important preprocessing step in 
the evaluation of FDG-PET data is the intensity normalization. This procedure removes 
differences in the absolute whole-brain intensity across different subjects so allowing a 
comparison of regional glucose utilization rates. However, there is still no consensus as to 
which reference region intensity normalization should be used.  
 
2.1. Introduction 
 
Research investigating the contribution of positron emission tomography with 
[F18]fluorodeoxyglucose (FDG-PET) in detecting dementia disorders has revealed differential 
patterns of a reduced regional cerebral metabolic rate for glucose in different types of dementia 
(Mielke et al., 1994; Salmon et al., 2000; Sakamoto et al., 2002; Jeong et al., 2005; Mosconi et 
al., 2006; Jagust et al., 2007; Samuraki et al., 2007). While AD patients show reduced glucose 
consumption in parietotemporal  and posterior cingulate cortices (Ishii et al., 2001, 2005; 
Yakushev et al., 2008; Schroeter et al., 2009), the reduced glucose metabolism of patients with 
FTLD is predominately located in frontotemporal and anterior cingulate cortices (Jeong et al., 
2005; Schroeter et al., 2007, 2008).  
Although the areas affected are sufficiently different in their anatomical distribution, it is 
necessary to run an intensity normalization procedure in order to compare their relative regional 
metabolic rate to those of healthy controls or with each other. This procedure removes 
12 
 
interindividual differences in the absolute whole brain intensity by relativizing the absolute 
metabolic rate for glucose in the whole brain to a reference area. Such differences can, for 
example, result due to different amounts of radiocontrast agent injected.  
A review of the current literature revealed the use of the following areas for normalization of 
FDG-PET scans of dementia patients: the cerebral metabolic rate for glucose (CMRglc: Mielke 
et al., 1994; Salmon et al., 2000; Ishii et al.,, 2001; Herholz et al., 2002; Mosconi et al., 2004; 
Samuraki et al., 2007; Del Sole et al., 2008; Yakushev et al., 2008, 2009), the cerebellum 
(Mielke et al., 1994; Minoshima et al., 1995; Ishii et al., 2001; Santens et al., 2001; Yakushev et 
al., 2008, 2009), the sensorimotor cortex (Minoshima et al., 1995; Santens et al., 2001; 
Sakamoto et al., 2002; Yakushev et al., 2008, 2009), the center of the midpontine slice 
(Minoshima et al., 1995; Mosconi et al., 2006), the visual cortex (Minoshima et al., 1995; 
Santens et al., 2001) and cluster-based normalization to the area with the highest activity in 
dementia patients (Yakushev et al., 2009).  
As recently pointed out by Yakushev et al. (2008), the appropriate reference area should be 
maximally stable in patients and in healthy controls, minimally susceptible to external 
physiological stimuli, unaffected by the disease of interest and reliable and easy to determine. 
Moreover, because recent studies have shown that the chosen reference area is also important 
for diagnostic accuracy (Yakushev et al., 2008, 2009), we suggest adding a further criterion to 
this description for practical clinical reasons: The area should allow the most accurate distinction 
between different clinical diagnoses. This is the case if the reference area offers a maximum 
contrast of the differences in glucose metabolism between patients and healthy controls or 
between groups of patients with different disorders, so allowing easier detection and 
differentiation of these. 
As most studies use either intensity normalization to the CMRglc (mean metabolic rate for 
glucose in the whole brain) or to cerebellar glucose consumption, we compared these two 
methods with respect to their superiority in both detecting dementia and also in differentiating 
between different types of dementia. These aspects are not necessarily the same, because 
normalizing the data to a specific region can either increase or decrease the power of statistical 
tests between different groups (Ishii et al., 2001; Yakushev et al., 2008; Yakushev et al., 2009). 
This strongly depends on the differences between groups in the reference areas. These are not 
the same for the comparison of clinical patients to healthy controls or to groups of patients with 
different disorders. For example, an earlier study showed the cerebellar glucose uptake to be 
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little affected in patients with AD while the CMRgluc was significantly reduced compared to 
healthy controls (Kushner et al., 1987). For that reason, we hypothesize differential effects of 
normalization for either the diagnosis or differentiation of dementia syndromes.  
 
2.2. Methods 
 
2.2.1. Subjects 
We analyzed FDG-PET data of 19 patients (Table 2.1) with an early stage of probable AD, 13 
patients with an early stage of FTLD and 10 control subjects. Probable AD was diagnosed 
according to the original and revised NINCDS-ADRDA criteria (McKhann et al., 1984; Dubois et 
al., 2007). Diagnosis of FTLD was based on criteria suggested by Neary et al. (1998). The 
control group included people who visited the Day Clinic of Cognitive Neurology at the 
University of Leipzig with subjective memory complaints, which were not objectively confirmed 
by a comprehensive neuropsychological and clinical evaluation. FDG-PET for these subjects 
was conducted for diagnostic reasons within the clinical assessment. This control group was 
chosen because in clinical practice it is crucial to discriminate between these subjects and 
patients with an early stage of dementia. Informed consent was obtained from all subjects. The 
research protocol was approved by the ethics committee of the University of Leipzig, and was in 
accordance with the latest version of the Declaration of Helsinki. 
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Table 2.1 Subject group characteristics. 
 Controls AD FTLD ANOVA (df, F, p) 
Number 10 19 13 - 
Male / female 6 / 4 7 / 12 6 / 7 - 
Age (years) 55.1±5.0 62.6±6.0 61.1±6.6 2,5.26,0.009 
CDR  (score) 0.25±0.26 0.87±0.47 0.81±0.43 2,7.77,0.001 
CMRglc/CerMRglc ratio 1.20±0.06 1.08±0.06 1.11±0.08 2,7.52,0.002 
Mean ± standard deviation. AD Alzheimer’s disease, ANOVA Analysis of variance, CerMRglc cerebellar 
metabolic rate for glucose, CMRglc cerebral metabolic rate for glucose, CDR Clinical Dementia Rating 
Scale, FTLD Frontotemporal lobar degeneration. 
 
2.2.2. [F18]fluorodeoxyglucose positron emission tomography imaging 
All PET data were acquired on a Siemens ECAT EXACT HR+ scanner (CTI/Siemens, Knoxville, 
TN, USA) under a standard resting condition in 2-dimensional (2D) mode. The 2D acquisition 
mode was used because it allows a better quantification of the PET data due to lower scatter 
radiation. Sixty-three slices were simultaneously collected with an axial resolution of 5 mm full 
width at half maximum (FWHM) and in-plane resolution of 4.6 mm. After correction for 
attenuation, scatter, decay and scanner-specific dead time, images were reconstructed by 
filtered back-projection using a Hann-filter of 4.9 mm FWHM. The 63 transaxial slices obtained 
had a resolution of 128*128 voxels with an edge length of 2.45 mm.  
 
2.2.3. [F18]fluorodeoxyglucose positron emission tomography data analysis 
The resultant ECAT volume files were separated into single frames (ANALYZE-format) using 
the import tool from the program MRIcro (http://www.sph.sc.edu/comd/rorden/mricro.html) and 
the last three frames à 10 minutes, starting from 30 to 60 minutes post injection, of each patient 
were chosen for further analysis. SPM5 (Statistical Parametric Mapping software: 
http://www.fil.ion.ucl.ac.uk/spm/) implemented in Matlab 7.7 (MathWorks Inc., Sherborn, MA) 
was used for further processing and statistical analysis. Each patient’s frames were spatially 
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realigned to minimize inter-frame motion artefacts and a mean image of these three frames was 
calculated for each patient (Figure 2.1).  
The cerebellar metabolic rate for glucose (CerMRglc) was obtained from a volume of interest 
(VOI), which was defined in three adjacent slices of the superior part of the right and left 
cerebellar hemispheres using the program P-Mod 
(http://www.pmod.com/technologies/index.html) supervised by an experienced physician trained 
in nuclear medicine. PET image sets were spatially normalized and smoothed using a Gaussian 
filter of 12 mm FWHM. To make the comparison of both reference regions more reliable we 
repeated the preprocessing procedure with a partial volume effect correction added prior to 
spatial normalization of the data using the modified Müller-Gärtner method (Müller-Gärtner et al., 
1992; Rousset et al., 1998) implemented in the PVELab software (Quarantelli et al., 2004). The 
intensity normalization to the cerebellum was performed using the ImCalc tool provided by SPM 
whereby each voxel of the preprocessed mean images was divided by the individual baseline 
intensity values obtained from the VOIs in the cerebellum. For normalization to CMRglc, we 
used proportional scaling in the SPM “global normalization” option, with global mean as the 
arithmetical mean of voxels above the threshold of 1/8 of the grand mean of the whole image. 
We ran the same voxel-based statistical analysis with both normalization methods, with and 
without an additional partial volume effect correction of the data. To account for group 
differences and for age-dependent reduction in glucose metabolism in elderly subjects (Salmon 
et al., 2000), age was included as a covariate in the statistical analysis.  
This procedure generated t-statistics for each voxel for different contrasts and constituted a 
statistical parametric map for the resulting t-values. The hypometabolic areas were investigated 
with a threshold of p<0.001 (uncorrected) and an extent threshold of 30 voxels. To analyze the 
intergroup differences, we used the spatial extent of clusters (number of voxels in all significant 
clusters) exceeding a probability threshold on a cluster level of p<0.05 (corrected for multiple 
comparisons) for each contrast. This statistical threshold was selected to capture a wide range 
of statistical differences but also to be high enough to distinguish separate clusters of metabolic 
differences.  
The CMRglc was compared to the CerMRglc in patient groups and controls by calculating a 
ratio of both metabolic rates: CMRglc/CerMRglc. Group comparisons for age, CDR (Clinical 
Dementia Rating Scale, Morris et al., 1993), and CMRglc/CerMRglc ratios were performed by 
conducting ANOVAs (analyses of variance). If an ANOVA revealed a significant between-group 
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effect, a Bonferroni t-test was calculated with a significance threshold of p < .05 (corrected for 
multiple comparisons, two-tailed). Group differences regarding sex were evaluated using a Chi-
square test for independence. The statistical analysis was performed with the commercial 
software package SPSS 17.0 (http://www.spss.com/statistics/).  
 
 
Figure 2.1 Schematic representation of the procedure for FDG-PET data handling and processing steps. 
 
2.3. Results 
 
The Chi-square test for independence did not reveal any statistical differences in sex between 
the groups [X²(2)=1.43; p=.49]. CDR scores were significantly different in the three groups 
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(Table 2.1). The post-hoc test revealed no difference in the mean CDR scores between both 
groups of dementia patients, indicating a similar level of severity of dementia syndrome 
[t(30)=.37; p=1.0]. As expected, both, early AD [t(27)=3.86; p=.002] and early FTLD 
[t(21)=3.571; p=.009] patients, had significantly higher CDR scores compared to the control 
group. The ANOVA also revealed a significant group difference in age. The two groups of 
dementia patients [t(30)=0.67; p=1.0] and FTLD patients and controls [t(21)=-2.39; p=.068] did 
not differ regarding age. There was a minor but significant difference in age between control 
subjects and AD patients [t(27)=-3.36; p=.008]. Accordingly age was included as covariate in 
the further analysis. Likewise, the groups differed significantly in CMRglc/CerMRglc ratios. The 
comparison of healthy controls with patients with the Bonferroni t-test revealed a reduced ratio 
in FTLD [t(21)=2.47; p=.025] and AD patients [t(27)=4.14; p=.001], while the difference between 
both groups of patients was not significant [t(30)=-0.94; p=1.0]. 
 
Table 2.2 Extension of hypometabolic brain regions for different contrasts with global and with 
cerebellar normalization. 
 Global normalization  Cerebellar normalization  
Contrast Cluster extent Maximal p-value Cluster extent Maximal p-value 
AD < Controls 7988 3.05E-010 14649 2.25E-013 
FTLD < Controls 11089 1.34E-013 17742 1.11E-016 
Controls < AD 7268 1.95E-009 n.s. n.s. 
Controls < FTLD 7863 1.62E-009 n.s. n.s. 
FTLD < AD 20069 <1.0E-20 4419 8.42E-05 
AD < FTLD 25704 <1.0E-20 8533 3.04E-10 
The size is represented by the sum of all clusters (in voxels) which exceeded an uncorrected threshold p 
< 0.001 on the voxel level with cluster extension k ≥ 30 voxels and p < 0.05 (corrected) on the cluster 
level. AD Alzheimer’s disease, FTLD Frontotemporal lobar degeneration, n.s. not significant. 
 
Table 2.2 and Figure 2.2 list the cluster extent (voxels) of differences detected for both types of 
intensity normalization. The statistical analysis after normalization to the CMRglc or to the 
CerMRglc revealed significant hypometabolism (Figure 2.3a) of AD patients relative to controls 
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in parietal, temporal, frontal and posterior cingulate cortices. The extension of significant 
clusters was almost twice the volume with normalization to CerMRglc compared to 
normalization to CMRglc. In the comparison of FTLD patients to healthy controls, the patients 
showed a significantly decreased metabolic rate in frontal, temporal and anterior cingulate 
cortices for both reference areas, but more extended regions of hypometabolism with cerebellar 
normalization.  
 
 
Figure 2.2 Extension of clusters with significantly reduced metabolic rate of glucose exceeding an 
uncorrected threshold of p < 0.001 on the voxel level (extent threshold k≥30 voxels) and a threshold of 
p<0.05 (corrected) on the cluster level for different contrasts with cerebral and cerebellar normalization. 
AD Alzheimer’s disease, FTLD Frontotemporal lobar degeneration.  
19 
 
 
Figure 2.3 a) Reduced relative glucose metabolism (p<0.001 uncorrected, extent threshold ≥30 voxels) in 
patients with Alzheimer’s disease (AD) and in patients with frontotemporal lobar degeneration (FTLD) 
relative to control subjects with normalization to the cerebellar and to the cerebral (global) metabolic rate 
for glucose. b) Reduced glucose metabolism in FTLD relative to AD patients and in AD relative to FTLD 
patients normalized to the cerebellar or to the cerebral metabolic rate for glucose. Anatomical convention. 
 
The reverse contrasts (controls < patients) showed reduced glucose metabolism in control 
subjects relative to AD and FTLD patients only with global normalization (Figure 2.4). However, 
no significantly lower metabolism was found in the statistical analysis with normalization to the 
cerebellum. This increased metabolic rate of AD and FTLD patients relative to control subjects 
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was located in the cerebellum in both groups and additionally in the sensorimotor and auditory 
cortices in the AD group and in parietal, posterior temporal and occipital regions in the FTLD 
group.  
 
 
Figure 2.4 Areas of apparent relative hypermetabolism (p<0.001 uncorrected, extent threshold ≥30 
voxels) obtained with normalization to the CMRglc in patients with Alzheimer’s disease (AD) and 
frontotemporal lobar degeneration (FTLD) relative to control subjects. No relative hypermetabolism was 
detected with cerebellar normalization (not shown). Anatomical convention. 
 
Comparison between the AD and FTLD patients revealed a somewhat different pattern with 
regard to normalization method used (Figure 2.3b). AD patients had a significantly reduced 
regional CMRglc in parietal, posterior temporal and occipital cortices compared to patients with 
FTLD. For this contrast, the CMRglc normalization revealed much more widely extended areas 
of significantly reduced glucose metabolism than cerebellar normalization. A similar pattern of 
differentiation for both reference areas was also obtained for the reverse contrast. Regional 
CMRglc in FTLD relative to AD patients was substantially reduced in frontal, anterior temporal 
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and anterior cingulate cortices, whereas the statistical analysis with CMRglc normalization also 
revealed larger areas of significantly reduced metabolic rate compared with normalization to 
CerMRglc.  
The statistical analysis with an additional partial volume effect correction of the data in the 
preprocessing revealed a similar pattern of hypometabolism differentiation for all comparisons 
depending on the reference area for normalization procedure (data not shown).  
 
2.4. Discussion 
 
The statistical analysis revealed a differential effect of both normalization procedures for 
comparison of dementia patients to either control subjects or to patients with a different type of 
dementia. These results are highly relevant for differential diagnosis of dementia. Consistent 
with previous studies which compared the two reference areas for AD (Ishii et al., 2001; 
Yakushev et al., 2008), cerebellar normalization was superior to global normalization in 
differentiating between controls and both groups of dementia patients. Quantitatively, the extent 
of areas with detected hypometabolism in patients was almost twice as large for the AD group 
and almost one and a half times as large for the FTLD group with cerebellar normalization 
relative to global normalization. This indicates a clear advantage of the first reference area for 
the detection of dementia. The locations of hypometabolic areas were similar to previous reports 
both for patients with probable AD (Ishii et al., 2001; Buchert et al., 2005) and for patients with 
FTLD (Jeong et al., 2005, Schroeter et al., 2007, 2008).  
An opposite pattern for both reference areas was obtained in the comparison of patients with 
probable AD and FTLD. The contrast for hypometabolic regions in AD relative to FTLD patients 
showed a reduced regional CMRglc in occipital, posterior temporal and parietal cortices. 
Surprisingly, the extent of significant clusters was three times as large with CMRglc 
normalization as with normalization to CerMRglc. The reverse contrast revealed a similar 
tendency depending on the reference area used. Regional CMRglc in FTLD patients was 
reduced in frontotemporal areas and the cluster size was in fact almost five times as large with 
normalization to the CMRglc. To our knowledge, this is the first comparison between 
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qualitatively different groups of dementia patients investigating the effect of the reference area. 
The results of this comparison indicate that although the CMRglc does not appear to be the 
optimal choice as reference area for detecting dementia, it has a clear advantage in 
distinguishing between different dementia syndromes.  
The differential effect of both reference areas can be explained regarding the CMRglc / 
CerMRglc ratio. This ratio did not differ significantly between both groups of patients and was 
lower than that of healthy controls. For this reason, normalization to the CMRglc does not 
remove between-group differences in the global metabolism for both patient groups, as it does 
in the comparison with healthy controls, but it actually increases the statistical power due to the 
higher CMRglc compared with CerMRglc and due to the higher signal-to-noise ratio with 
normalization to the CMRglc compared with the cerebellum as reference area. The higher 
signal-to-noise ratio with normalization to the CMRglc is a result of the greater number of voxels 
used for the estimation of the mean intensity in the whole brain compared with the cerebellar 
reference area, so reducing the effect of stochastic noise. This result has important implications 
for the differentiation between different types of dementia. Studies investigating the diagnostic 
accuracy of neuropsychological testing for the differential diagnosis of AD vs. FTLD have 
revealed an overall accuracy of about 90% for correctly classifying patients with AD. However, 
accuracy was substantially lower for correctly classifying FTLD patients, with values of only 
about 64% to 77% (Rascovsky et al., 2002; Walker et al., 2005). Comparing FDG-PET scans of 
dementia patients not only to those of healthy controls but also to the disease-specific pattern of 
regional CMRglc in different kinds of dementia might significantly facilitate and improve the 
differential diagnosis of these as has been shown by Mosconi et al. (2008). To maximally 
increase the efficiency of these comparison-based differentiations, it is necessary to take into 
account that the same reference area for intensity normalization can, on the one hand, increase 
the statistical power in a comparison with healthy controls. However, on the other hand it can 
also worsen the differentiation of groups of patients. Therefore, thorough evaluation of different 
reference regions with respect to the diagnostic questions is required. 
The apparent relative hypermetabolism of dementia patients obtained with global normalization 
has been reported previously but only in AD patients (Salmon et al., 2000; Ishii et al., 2001; 
Samuraki et al., 2007). In our study, we also found a similar effect for FTLD patients. This 
hypermetabolism seems to be an artifact of global normalization, as we did not find regional 
hypermetabolism if the cerebellum was chosen as reference area. This finding is also supported 
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by the significantly different ratio of the global to the cerebellar mean between control subjects 
and dementia patients. Because earlier studies have shown the cerebellar metabolic rate to be 
preserved in dementia (Kushner et al., 1987), differences in the ratio can mainly be attributed to 
the reduced CMRglc in the patient groups. Therefore, intensity normalization to the CMRglc 
removes global uptake differences between groups, which results in method-created 
hypermetabolism in some relatively preserved regions in dementia patients. This result and 
conclusion are in accordance with observations in AD patients made in previous studies 
(Buchert et al., 2005; Yakushev et al., 2008). Moreover, our results are in line with recent 
studies using other imaging modalities that indicated a regional hyperperfusion as an artifact 
created by the normalization to the global mean in neurological disorders such as Parkinson’s 
disease (Borghammer et al., 2009). Additionally, our results may indicate that besides the 
cerebellum the primary cortices are unaffected in the early stages of both types of dementia.  
Our study suggests applying normalization to the CerMRglc for diagnosis, and normalization to 
the CMRglc for differential diagnosis of dementia syndromes, at least for AD and FTLD. 
Moreover, both normalization approaches could be easily applied in the clinical environment. 
First of all, normalization to the CMRglc is already integrated into the SPM software package. 
Secondly, normalization to the cerebellum provides an easily determined and reliable alternative 
to the sensorimotor cortex which is also frequently used (Minoshima et al., 1995; Santens et al., 
2001; Sakamoto et al., 2002; Yakushev et al., 2008, 2009), but which has the disadvantage that 
the surface appearance and structural organization varies greatly from subject to subject (White 
et al., 1997; Geyer et al., 1999).  
Normalization to the visual cortex, which is also used, can be problematic because of it’s 
susceptibility to visual stimulation (Newberg et al., 2005), thereby increasing the variance 
among the data and so reducing the sensitivity of statistical tests. A similar problem of increased 
variance in the data might occur with normalization to the center of the midpontine slice. Due to 
the small size of this VOI, extracting data from such a small region would result in a decreased 
signal-to-noise ratio.   
Recently it has been suggested to first use CMRglc normalization to get the cluster with the 
highest metabolic rate in the patient group (Yakushev et al., 2009).  As the next step, the 
absolute counts for each subject within this cluster are extracted and the FDG-PET data are 
normalized to these cluster-derived counts. Despite the fact that this normalization method 
provides a substantial increase in statistical power thus allowing good discrimination between 
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different groups, it has several disadvantages. For one thing, it is a circumstantial algorithm, 
requiring additional processing steps, which might be difficult to apply in the clinical environment. 
Furthermore, it is a data-driven process with limited generalizability to data of new patients, 
because the position of the region with the highest metabolic rate and its extent may differ 
substantially across patients with the same type of dementia.  
 
2.5. Conclusions 
 
The present study investigated the impact of normalization strategies on diagnostic accuracy in 
dementia. Whereas cerebellar normalization seems to be superior in early detection and 
diagnosis of dementia, normalization to the cerebral metabolic rate for glucose may be superior 
in differential diagnosis of various dementia syndromes.  
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3. Multimodal imaging in dementia using [F18]fluorodeoxyglucose positron emission 
tomography and magnetic resonance imaging 
 
Different imaging techniques have been shown to provide useful information to improve 
understanding of functional mechanisms and development of various neurodegenerative 
disorders such as AD and FTLD (Mielke et al., 1994; Salmon et al., 2000; Chetelat et al., 2008; 
Desgranges et al., 2007; Schroeter et al., 2007, 2009). Additionally, in recent research various 
biomarkers have been reported to differentiate between early stages of dementia and healthy 
control subjects or between different types of neurodegenerative disorders, suggesting an 
integration of these would improve diagnostic accuracy of dementia (Hoffman et al., 2000; 
Rosen et al., 2002; Diehl et al., 2004; Jeong et al., 2005; Diehl-Schmid et al., 2007; Edison et al., 
2007; Fung and Stoeckel, 2007; Sabri et al., 2008; Schroeter et al., 2007, 2009). The following 
section investigates differential changes in FDG-PET and MRI in AD and FTLD patients and 
systematically compares the use of these biomarkers for detection and differentiation of both 
dementia syndromes. 
 
3.1. Introduction 
 
For the detection of dementia, accuracy rates significantly above 90% have recently been 
reported using univariate and multivariate statistical approaches in magnetic resonance imaging 
(MRI) and [F18]fluorodeoxyglucose positron emission tomography (FDG-PET) (Hoffman et al., 
2000; Matsunari et al., 2007; Klöppel et al., 2008a; Davatzikos et al., 2008; Fan et al., 2008; 
Sadeghi et al., 2008). However, the differentiation of the two most common types of dementia, 
namely Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD), is still 
problematic. For this differentiation, accuracy rates ranging between 84 and 89% are still in 
need of improvement, especially due to a substantially lower sensitivity compared with 
specificity of actual methods (Knopman et al., 2005; Klöppel et al., 2008a; Davatzikos et al., 
2008). Nevertheless, the use of biomarkers has significantly helped to improve diagnostic 
accuracy compared with diagnoses based solely on clinical and neuropsychological evaluation 
(Raskovsky et al., 2002; Dubois et al., 2007). For these reasons, recent studies have suggested 
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to incorporate imaging findings into criteria for diagnosis of dementia (Dubois et al,. 2007; Kipps 
et al., 2009). 
For AD patients imaging studies have shown reduced glucose consumption mainly in 
parietotemporal and posterior cingulate cortices (Ishii et al., 2001, 2005; Yakushev et al., 2008; 
Kanda et al., 2008; Schroeter et al., 2009) and structural changes in the hippocampus and 
entorhinal area relative to healthy controls (Van de Pol et al., 2006; Kanda et al., 2008; 
Schroeter et al., 2009). In FTLD patients, atrophy and reduced metabolic rate for glucose have 
been reported to be predominately located in the medial thalamus, amygdala and in 
frontotemporal and anterior cingulate cortices  (Ishii et al., 2005; Jeong et al., 2005; Schroeter et 
al., 2007, 2008; Kanda et al., 2008). 
Different univariate and multivariate approaches were proposed for the detection and 
differentiation of these changes to enable a more accurate detection and differential diagnosis 
of dementia. Univariate approaches range from the most frequently used voxel-based 
morphometry (VBM) at the whole-brain or region-of-interest (ROI) level (Rosen et al., 2002, 
2005; Desgranges et al., 2007; Rabinovici et al., 2007; Chetelat et al., 2008) to volumetric 
assessment of specific regions (Perry et al., 2006) and measurement of cortical thickness 
(Lerch et al., 2005; Querbes et al., 2009). For multivariate differentiation of different types of 
dementia support vector machine classification (SVM) is used based on whole-brain voxel 
information (Klöppel et al., 2008a) or most frequently on ROI values (Davatzikos et al., 2008; 
Fung et al., 2007; Fan et al., 2008; Chaves et al., 2009; Horn et al., 2009). However, a major 
problem of the ROI-based approach is the limited generalizability of the trained classifier, 
because the ROIs are selected based on features showing a between-group differentiation in 
the same groups in a univariate analysis. Although ROIs selected with this method provide a 
good discrimination between groups used in these specific studies, they might show significantly 
reduced discrimination power when applied to new data sets. This could be the case if the 
selected regions just detect differences between groups, which are not necessarily attributed to 
the specific neurodegenerative disorder. 
Here, we investigate the contribution of multimodal imaging using FDG-PET and high-resolution 
MRI for a better understanding and differentiation of AD and FTLD. We apply VBM and SVM as 
the most frequently used univariate and multivariate approaches to evaluate their contribution 
for understanding, detection and differentiation of dementia in multimodal imaging. Additionally, 
we apply SVM classification on data extracted from ROIs based on disorder-specific metabolic 
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reductions and atrophy reported in comprehensive meta-analyses investigating AD and FTLD. 
This method allows a better generalization of our classification algorithms to other clinical 
centers and ensures that only disorder-specific changes are used for SVM based discrimination. 
We hypothesize that common use of different imaging modalities might substantially improve 
early detection and differentiation of dementia. 
 
3.2. Methods 
 
3.2.1. Subjects 
Table 3.1 Subject group characteristics 
 Controls AD FTLD ANOVA (df,F,P) 
Number 13 21 14 - 
Male/Female 7/6 9/12 7/7 - 
Age (years) 53.9±6.0 61.1±6.7 60.8±6.4 2, 5.76, 0.006 
CDR (score) 0.23±0.26 0.71±0.25 0.82±0.42 2, 13.93, 0.000 
Mean ± standard deviation. AD Alzheimer’s disease, ANOVA analysis of variance, CDR Clinical Dementia 
Rating Scale, FTLD frontotemporal lobar degeneration. 
 
We analyzed FDG-PET and T1-weighted MRI data of 21 patients (Table 3.1) with an early stage 
of probable AD, 14 patients with an early stage of FTLD and 13 control subjects. Probable AD 
was diagnosed according to the original and revised NINCDS-ADRDA criteria (McKhann et al., 
1984; Dubois et al., 2007). Diagnosis of FTLD was based on criteria suggested by Neary et al. 
(1998). The control group included subjects who visited the Day Clinic of Cognitive Neurology at 
the University of Leipzig with subjective memory complaints, which were not objectively 
confirmed by a comprehensive neuropsychological and clinical evaluation. FDG-PET and MRI 
for these subjects was conducted for diagnostic reasons within the clinical assessment. This 
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control group was chosen because, in clinical practice, it is crucial to discriminate between 
these subjects and patients with an early stage of dementia. Informed consent was obtained 
from all subjects. The research protocol was approved by the Ethics Committee of the 
University of Leipzig, and was in accordance with the latest version of the Declaration of 
Helsinki. 
 
3.2.2. Data acquisition 
a) Magnetic resonance imaging data 
For each subject, a high-resolution T1-weighted MRI scan was obtained, consisting of 128 
sagittal slices adjusted to AC-PC line and a with slice thickness of 1.5mm and pixel size of 
1×1mm². MRI was performed on two different 3T scanners (MedSpec 30/100, Bruker Biospin, 
Ettlingen Germany and Magnetom Trio, Siemens, Erlangen, Germany) using two different T1-
weighted sequences (MDEFT or MP-RAGE with TR=1300ms, TI=650ms, TE=3.93ms or 
TE=10ms; FOV 25×25 cm²; matrix = 256×256 voxels). On the MedSpec scanner, only the 
MDEFT-sequence and on the Magnetom Trio scanner, either MDEFT or MP-RAGE sequences 
were used.  
 
b) [F18]fluorodeoxyglucose positron emission tomography data 
Each subject also underwent FDG-PET imaging either a few a weeks before or after the MRI 
scan. All PET data were acquired on a Siemens ECAT EXACT HR+ scanner (CTI/Siemens, 
Knoxville, TN, USA) under a standard resting condition in 2-dimensional (2D) mode. The 2D 
acquisition mode was used because it allows a better quantification of the PET data due to 
lower scatter radiation. Sixty-three slices were simultaneously collected with an axial resolution 
of 5 mm full width at half maximum (FWHM) and in-plane resolution of 4.6 mm. After correction 
for attenuation, scatter, decay and scanner-specific dead-time, images were reconstructed by 
filtered back-projection using a Hann-filter of 4.9 mm FWHM. The 63 transaxial slices obtained 
had a matrix of 128×128 voxels with an edge length of 2.45 mm. 
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3.2.3. Image processing  
The procedure described below has been specifically designed for this study, aiming at a most 
accurate co-processing of FDG-PET and MRI data to allow the comparison of quantitative and 
qualitative differences in the distribution of hypometabolic and atrophic regions in both groups of 
dementia patients (Figure 3.1). All image-processing steps and the subsequent univariate 
statistical analysis were carried out using the SPM5 software package (Statistical Parametric 
Mapping software: http://www.fil.ion.ucl.ac.uk/spm/) implemented in Matlab 7.7 (MathWorks Inc., 
Sherborn, MA). SVM classification was conducted with the LIBSVM software (Chang and Lin, 
2001) using the Matlab interface.  
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Figure 3.1 Schematic representation of the procedure for FDG-PET and MRI data handling and 
processing steps. FDG-PET [F18]fluorodeoxyglucose positron emission tomography, MRI magnetic 
resonance imaging. 
a) Magnetic resonance images 
The MR images were first interpolated to get an isotropic resolution of 1×1×1 mm³. The 
resultant MR images were coregistered on their respective FDG-PET images and bias corrected 
for inhomogeneity artifacts using the Unified Segmentation Approach described in detail by 
Ashburner and Friston (2005). This specific method performs a better coregistration of images 
from different modalities and allows a more accurate segmentation due to the bias correction. A 
further reason to use this approach was that the straightforward coregistration implemented in 
the PVElab software described later sometimes failed. We used this software for automatic 
partial volume correction of the FDG-PET images. The coregistered MR images were 
processed using the DARTEL approach (Ashburner, 2007) to enable a voxel-based 
morphometric comparison. This approach registers all gray matter (GM) and white matter (WM) 
images to an averaged-size template created from all subjects used in this study and preserves 
the total amount of signal from each region in the images. Subsequently, the images were 
smoothed using a Gaussian kernel of 12 mm FWHM. This smoothing factor, although higher 
then usual MR kernels, was selected based on extensive tests, because it allows the optimal 
coevaluation with lower resolution FDG-PET images.  
 
b) [F18]fluorodeoxyglucose positron emission tomography data 
Within the common registration with MRI data using the Unified Segmentation Approach 
described above, PET images were interpolated to the same voxel size as the MR images, 
namely 1×1×1 mm³. This processing does not introduce any additional noise into the PET 
images. However, in our experience, it substantially improves the subsequent partial volume 
effect (PVE) correction of voxels representing GM intensities using the modified Müller-Gärtner 
method (Müller-Gärtner et al., 1992; Rousset et al., 1998). Due to the interpolation, they are 
exactly overlaid with the MR tissue class images of the same subject obtained from the 
segmentation step in the PVE approach. Thus, the within-voxel correction is done only for those 
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voxels directly overlaying the GM structures in the MR images. Instead of smoothing the MR 
data to the resolution of PET data and thus loosing the exact quantitative and qualitative 
information of GM distribution, which is usually done in the PVE correction, the interpolation of 
FDG-PET preserves this information. This allows a more accurate correction of atrophy effects 
onto glucose utilization and so a better quantitative comparison of atrophy and hypometabolism 
in neurodegenerative disorders. The subsequent PVE correction including all image processing 
steps was done by using the automatic algorithm implemented in the PVElab software package 
(Quarantelli et al., 2004). Because the modified Müller-Gärtner method sets all WM voxel values 
to the mean WM intensity value, these regions do not contain any further valuable regional 
information after the PVE correction. For this reason, all voxels belonging to WM were masked 
using the ImCalc function in the SPM5 software package by filtering this specific intensity in the 
whole image. After the PVE correction, the DARTEL flow fields calculated from the MR images 
were applied to their respective PET images to obtain an anatomically exact overlap between 
GM and PET images of all subjects with modulation to preserve the total amount of signal from 
each region. In the same way as the MR data, the PET data were smoothed by a Gaussian 
kernel of 12 mm FWHM. Finally, the FDG-PET data were intensity normalized using cerebellar 
ROIs to account for individual differences in global PET measures. This region has been shown 
to be least affected in mild to moderate stages of AD (Ishii et al., 1997). Additionally, 
normalization to this region improves the statistical discrimination between dementia patients 
and control subjects in comparison to other regions reported in the literature (Yakushev et al., 
2008, 2009; Dukart et al., 2010).  
 
c) Masking 
The MR and PET images obtained as described above were masked to avoid contamination by 
misclassified voxels. Voxels lying between WM and ventricular cerebrospinal fluid tend to be 
misclassified as GM voxels due to their similar intensity. The mask was obtained after extensive 
testing by excluding all voxels in the first and the last template created by the DARTEL 
approach with a probability of below 0.2 for belonging to GM and including only the voxels that 
exceed this threshold in both templates. This mask was applied twice: firstly prior to smoothing 
to avoid misclassification, and secondly, after the smoothing to avoid big edge effects. WM 
images were exclusively masked using the same mask to avoid overlaps between GM and WM 
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voxels due to smoothing. The masked images were used for the subsequent VBM and SVM 
analysis of the data.  
 
d) Region-of-interest extraction 
ROI coordinates were extracted from two comprehensive, systematic and quantitative meta-
analyses investigating biomarkers of AD and FTLD in MR and FDG-PET images. The meta-
analyses included a total number of 1618 patients (AD/FTLD: 1351/267) and 1448 healthy 
control subjects (1097/351) (Schroeter et al., 2007, 2009). These meta-analyses extracted the 
prototypical networks of AD and FTLD by applying what is currently the most sophisticated and 
best-validated of coordinate-based voxel-wise meta-analyses, anatomical likelihood estimate. In 
the FTLD meta-analyses (Schroeter et al., 2007) only coordinates which are common to all 
subgroups of FTLD patients were used. Because the coordinates in both meta-analyses were 
reported in the Talairach space, they were transformed to MNI space according to a formula 
proposed by Matthew Brett (published on the Internet: 
http://www.mrccbu.cam.ac.uk/Imaging/Common/mnispace.shtml). DARTEL preprocessed data 
are registered to an averaged size template created from all subjects in this study. To transform 
these data to the MNI space we normalized them to an a priori MNI template in SPM by using 
affine-only spatial normalization. Due to the affine-only transformation, our images still differed 
in shape from the MNI template, so some reported coordinates were slightly outside of the 
anatomic regions in our imaging data. In this case, the center coordinates for the ROIs were 
moved slightly towards the closest point of the corresponding anatomical region reported in the 
meta-analyses. ROIs were selected using the 3D fill tool in the MRIcron software package 
(http://www.sph.sc.edu/comd/rorden/mricron).  
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Figure 3.2 Regions of interest extracted from gray matter (left) and FDG-PET (right) data for AD and 
FTLD patients and used for support vector machine classification projected onto a glass brain (top) and 
onto an axial slice (bottom). AD Alzheimer’s disease, FDG-PET [F18]fluorodeoxyglucose positron 
emission tomography, FTLD frontotemporal lobar degeneration, GM gray matter, ROIs regions of interest. 
 
Separate ROI masks were created for MR and FDG-PET images based on the origin of the 
peak values reported in the meta-analyses. Each ROI was restricted to a sphere with a radius of 
5 mm around the reported coordinate (Figure 3.2). Additionally, to increase the signal-to-noise 
ratio, all zero voxels and edge voxels with an intensity deviation of 13 intensity units in the 
MRIcron 3D fill tool were excluded from the ROI. The edge voxel restriction excludes all voxels 
at the edge of the smoothed GM structures within the sphere. These voxels carry much less 
information due to their further distance from the GM structures in the unsmoothed data and so 
decrease the signal-to-noise ratio in the corresponding ROI.  
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3.2.4. Statistical analysis 
a) Voxel-based morphometry 
To evaluate group differences between AD, FTLD and control subjects, voxel-wise independent 
sample t-tests were calculated for the whole-brain for FDG-PET, GM and WM images. Age and 
sex were included as covariates in all t-tests to account for age-dependent reduction in elderly 
subjects (Salmon et al., 2000). In order to exclude possible scanner type or sequence effects on 
the between group differentiation, further analyses were calculated. Firstly, the analysis was 
repeated twice for the subsets of MDEFT and MP-RAGE images separately. Secondly, the 
analysis was performed again for the subset of MR images from the Siemens scanner, both with 
and without the acquisition sequence being considered as an additional covariate. 
Hypometabolic and atrophic regions were investigated with a threshold of p<0.001 (uncorrected) 
on the voxel level and p<0.05 (corrected for multiple comparison) on the cluster level. To 
analyze the intergroup differences, we used the spatial extent of clusters (number of voxels in 
all significant clusters) exceeding this threshold. Due to the same resolution of FDG-PET and 
MR data after the interpolation the number of significant voxels can be used for a quantitative 
comparison of atrophy and hypometabolism in both groups. 
 
b) Support vector machine classification 
Multivariate pattern classification, as described in Klöppel et al. (2008a), was performed with a 
linear kernel by identifying a separating hyperplane that maximizes the distance between 
different clinical groups based on whole-brain or ROIs information. The cross-validation of the 
trained SVM was performed by using the leave-one-out method. This procedure iteratively 
leaves out the information of each subject and trains the model on the remaining subjects for 
subsequent class assignation of the person that was not included in the training procedure. This 
validation method enables the generalization of the trained SVM to data that have never been 
presented to the SVM algorithms previously. The reported accuracy is the percentage of 
subjects correctly assigned to the clinical diagnosis. Usually SVM classification is performed 
without smoothing of the data, because single voxels are assumed to contain information, for 
example, for prediction of future action based on functional MR images. However, in 
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neurodegenerative disorders single voxels are unlikely to contain generalizable information due 
to a limited across-subject registration of MR and FDG-PET images. Although SVM 
classification based on unsmoothed data has been shown to differentiate reasonably between 
different groups (Klöppel et al., 2008a), an additional smoothing should make this approach 
more reliable and generalizable to new data. To control for the effect of smoothing we ran the 
same whole-brain classification twice for GM, PET and for integration of GM and PET in the 
same vector with and without smoothing.  
We performed the whole-brain SVM classification using GM, WM or FDG-PET images 
separately and by combining information from different modalities. For the SVM classification, 
all data of a subject are transformed into a vector, with information of an additional modality 
simply attached by extending the vector. Additionally, we repeated the whole-brain SVM 
classification by adding MR to FDG-PET information combining both modalities in a single 
image. ROI-based SVM classification was performed on data extracted from smoothed images 
separately for GM and FDG-PET images and also by integrating information from both 
modalities in a single vector. In order to reduce the number of voxels in the ROI-based 
classification, only nonzero voxels were included in the vector. This was done because 
otherwise the whole-brain SVM classification is a highly memory-consuming approach. To 
ensure that our classification results were not based on factors randomly discriminating between 
groups, we reran the whole-brain and ROI-based classification for comparison 30 times by 
randomly assigning all subjects to the three groups independently from the clinical diagnosis 
and calculating the classification accuracy by using the leave-one-out procedure described 
above. 
 
c) Group comparisons 
Group comparisons for age and CDR (Clinical Dementia Rating Scale, Morris, 1993) were 
performed by conducting ANOVAs (analyses of variance). If an ANOVA revealed a significant 
between-group effect, a Bonferroni t-test was calculated with a significance threshold of p<.05 
(corrected for multiple comparisons, two-tailed). Group differences regarding sex were 
evaluated using a chi-square test for independent samples. The statistical analysis was 
performed with the commercial software package SPSS 17.0 (http://www.spss.com/statistics/).  
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3.3. Results 
 
The chi-square test for independent samples did not reveal any statistical differences in sex 
between the groups [χ²(2)=0.42;p=0.809]. CDR scores differed significantly in the three groups 
(Table 1). The post-hoc test revealed no differences in the mean CDR scores between both 
groups of dementia patients indicating a similar severity of dementia syndrome 
[t(33)=0.94;p=0.977]. As expected, both early AD [t(32)=5.36;p<0.001] and early FTLD 
[t(25)=4.35;p<0.001] had significantly higher CDR scores compared to the control subjects. The 
ANOVA also revealed a significant group difference in age. The two groups of dementia patients 
did not differ significantly in age [t(33)=0.16;p=1.0]. There was a minor but significant difference 
between AD patients and controls [t(32)=3.18;p=.008] and FTLD patients and controls 
[t(25)=2.86; p=.024]. To avoid any possible effects of age and sex, both variables were included 
as covariates in the further analysis. 
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3.3.1. Voxel-based morphometry 
 
Figure 3.3 Extension of clusters with significantly reduced metabolic rate of glucose or gray matter 
intensity exceeding an uncorrected threshold of p<0.001 on the voxel level and a threshold of p<0.05 
(corrected) on the cluster level for different contrasts. AD Alzheimer’s disease, FTLD frontotemporal lobar 
degeneration. 
  
Figures 3.3 and 3.4, and Table 3.2 illustrate significant reduction in GM values, WM values, and 
FDG-PET values in AD and FTLD patients relative to control subjects. AD patients showed 
extensive reduction in glucose utilization in precuneal, posterior cingulate, lateral parietal, 
posterior temporal, and left frontal cortices (Figure 3.4). GM values were significantly reduced in 
left frontal, left thalamic, parahippocampal, posterior cingulate, precuneal, lateral parietal, and 
posterior temporal regions. WM intensity reduction was mainly restricted to the splenium of the 
corpus callosum and to posterior regions predominating on the left side. The extension of 
significant clusters for hypometabolism substantially exceeded the extension of atrophy in most 
affected regions except for the thalamus (Figure 3.3). In FTLD patients, GM intensity reduction 
was observed predominately in medial and lateral regions of the frontal lobe but also extending 
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to the insula, left anterior temporal lobe, hippocampus, amygdala, thalamus, putamen and 
bilaterally to the head of nucleus caudatus (Figure 3.4). Hypometabolic regions were mainly 
restricted to cortical structures in the medial and lateral frontal cortices, left insula and left 
temporal lobe slightly extending to the parietal cortex. Significant WM intensity reductions were 
detected mainly in the anterior parts of the corpus callosum, peduncular tracts and in anterior 
regions. All reductions in GM, WM and FDG-PET values in FTLD patients were predominantly 
located on the left side (Figure 3.4). The extension of atrophy exceeded the reduction of glucose 
utilization in most significant structures except for dorsolateral regions of the prefrontal cortex. 
 
 
Figure 4 Reductions in glucose metabolism (red), gray matter intensity (blue) in top row, and white matter 
intensity (cyan) in bottom row in patients with Alzheimer’s disease (AD, top row) and frontotemporal lobar 
degeneration (FTLD). 
 
Comparing AD and FTLD patients, there was no difference in GM and WM values exceeding 
the significance threshold. Metabolic rate was substantially reduced in AD in comparison to 
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FTLD patients in posterior cingulate and precuneal regions. The reverse contrast did not reveal 
any significant reduction. Additional analyses for the different subgroups, separated by MRI 
scanner type or sequence and including the scan sequence as additional covariate did not 
reveal any substantial differences from the pattern described above. 
 
 
3.3.2. Suport vector machine classification 
Table 3.3 Accuracy rates for whole-brain and ROI-based SVM classification for FDG-PET and 
MRI 
 
AD, FTLD and 
Controls 
AD vs FTLD AD vs Controls 
FTLD vs 
Controls 
GM 
whole-brain 
72.9% 80.0% 88.2% 77.8% 
WM 
whole-brain 
66.7% 74.3% 79.4% 77.8% 
FDG-PET 
whole-brain 
81.3% 82.9% 94.1% 92.6% 
GM/ FDG-PET  
whole-brain 
79.2% 82.9% 94.1% 88.9% 
GM/WM/FDG-PET 
whole-brain 
77.1% 82.9% 91.2% 85.2% 
GM + FDG-PET 
whole-brain 
81.3% 88.6% 91.2% 88.9% 
GM 
ROIs 
56.3% 60.0% 82.4% 85.2% 
FDG-PET 
ROIs 
75.0% 80.0% 94.1% 85.2% 
GM/FDG-PET  
ROIs 
91.7% 94.3% 100.0% 92.6% 
Accuracy represents the percentage of subjects correctly assigned to the correct condition. AD 
Alzheimer’s disease, FDG-PET [18F]fluorodeoxyglucose positron emission tomography, FTLD 
frontotemporal lobar degeneration, GM gray matter, MRI magnetic resonance imaging, ROI region-of-
interest, SVM support vector machine, WM white matter. 
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Figure 3.5 Voxels most relevant for classification of both groups of patients and control subjects in FDG-
PET and MRI after SVM training. AD and FTLD vs Controls: Blue and light blue indicate decreased gray 
matter intensity or reduced metabolic rate that increase the likelihood of classification into a dementia 
group. Red and yellow indicate the opposite. AD vs FTLD: Blue and light blue indicate decreased gray 
matter intensity or reduced metabolic rate that increase the likelihood of classification into the AD group. 
Red and yellow indicate the opposite.  AD Alzheimer’s disease, FTLD frontotemporal lobar degeneration. 
MRI magnetic resonance imaging, PET positron emission tomography. 
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Multivariate classification of the data using SVM at the whole-brain level revealed the best 
discrimination accuracy for all three groups using FDG-PET, with 81% (chance level 33%), in 
comparison to GM and WM information, with lowest accuracy using WM information on its own 
(Table 3.3). The combination of metabolism and GM values in a single image revealed a similar 
accuracy for differentiation of the three groups, with higher accuracy for differentiation between 
both types of dementia, however, with slightly lower discrimination between dementia patients 
and control subjects. Whole-brain SVM classification for the three groups without smoothing 
revealed lower accuracy rates in all classifications in comparison to differentiation based on 
smoothed images. The accuracy increase due to smoothing ranged between 2 (GM) and 6% 
(FDG-PET). Figure 3.5 displays regions that were most influential in making binary classification 
between the AD, FTLD and control subjects based on smoothed whole-brain information. 
Accuracy based on ROIs from both meta-analyses using only GM information was substantially 
lower for differentiation between AD and FTLD patients in comparison with whole-brain 
classification. However, it was comparable to the whole-brain approach in differentiating 
between patients with both types of dementia and control subjects. ROIs extracted from FDG-
PET data showed slightly lower discrimination accuracy compared to whole-brain information. 
The best accuracy rates of all SVM classifications were obtained using combined information 
extracted from FDG-PET and GM data.  
 
Table 3.4 Differentiation rates for combined region-of-interest information from FDG-PET and 
MRI 
 Accuracy Sensitivity Specificity 
AD vs FTLD 94.3% 95.2%* 92.9% 
AD vs Controls 100.0% 100.0% 100.0% 
FTLD vs Controls 92.6% 85.7% 100.0% 
*Considering a correctly identified AD as a true positive. AD Alzheimer’s disease, FDG-PET 
[18F]fluorodeoxyglucose positron emission tomography, FTLD frontotemporal lobar degeneration, MRI 
magnetic resonance imaging.  
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This approach resulted in a classification accuracy of 92% for the differentiation of all three 
groups and an accuracy rate of 94% for differentiation between AD and FTLD patients. 
Sensitivity of this ROI-based classification ranged between 85.7% for FTLD and 100% for AD 
and specificity of 100% for discrimination of both types of dementia from control subjects (Table 
3.4) 
The classification accuracy in the 30 trials randomly assigning all subjects to the three groups 
resulted in a mean accuracy rate of 34±7.7% (mean ± standard deviation), ranging between 21 
and 52% for the ROI-based SVM classification, and 33.7±8.2% ranging between 12 and 50%for 
the whole-brain classification. 
 
3.4. Discussion 
 
In this study we performed a multimodal comparison and discrimination of dementia patients 
using FDG-PET and MRI. To enable a quantitative evaluation and comparison of differences in 
both imaging modalities, we developed a new preprocessing algorithm. This algorithm was 
designed to enable an accurate anatomical registration of both modalities. All processing steps 
were performed as far as possible simultaneously by applying the same deformations and 
preprocessing parameters to both modalities of the same subject. This procedure resulted in an 
accurate anatomical overlap of both imaging modalities and in an accurate between-subject 
registration, with both images having the same voxel size and approximately the same effective 
smoothness to allow a direct volumetric comparison of differences to control subjects in both 
imaging modalities.  
Previous studies have performed this comparison based mainly on qualitative differences by 
comparing the mean reduction of glucose and GM intensity values in specific regions with each 
other (Ishii et al., 2005; Chetelat et al., 2008; Kanda et al., 2008). Furthermore, in most studies, 
FDG-PET and MRI as biomarkers were investigated separately only for AD or FTLD patients 
relative to control subjects (Ishii et al., 2005; Kawachi et al., 2006; Desgranges et al., 2007). 
Hence, a direct comparison of the distribution of hypometabolism and atrophy in both disorders 
is limited due to different control groups and different processing algorithms. Only one study 
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compared AD patients to frontotemporal dementia (one subtype of FTLD) in both modalities 
(Kanda et al., 2008). However, the main disadvantage of this study is the missing PVE 
correction, which strongly restricts the interpretation and comparison of the distribution and 
amount of hypometabolic areas relative to atrophic regions. In addition, Kanda et al. (2008) do 
not provide a volumetric evaluation of the amount of hypometabolism and atrophy relative to 
each other.  
Due to the preprocessing algorithm described above our data allow the quantitative evaluation 
of differences between different types of dementia in different imaging modalities. By performing 
PVE correction we excluded that reductions in glucose metabolism can be ascribed to atrophy 
in these specific regions. Furthermore, the results of the VBM analysis in our study are not 
dependent on the MRI scanner or sequence used, as has been shown by additional analyses of 
different subgroups and by including the sequence as covariate. High discrimination rates in 
SVM, despite using different scanner types and sequences, indicate the reliability of our 
approach. This result is supportive of the potential of our approach to be applied to imaging data 
from different imaging centers and increases its potential value for clinical diagnostic 
applications.  
 
3.4.1. Results of voxel-based morphometry 
The statistical analysis revealed a differential pattern of atrophy and glucose hypometabolism in 
both types of dementia relative to control subjects. In AD, the amount of hypometabolism 
exceeded the amount of GM atrophy in most affected structures. This result is consistent with 
observations of hypometabolism exceeding atrophy in most affected areas reported in previous 
studies investigating AD (Matsunari et al., 2007; Samuraki et al., 2007; Chetelat et al., 2008; 
Kanda et al., 2008). However, the opposite pattern was observed for FTLD patients. In this 
group, the extent of atrophic regions was larger in comparison to hypometabolic regions relative 
to control subjects. Generally, the amount of GM and WM atrophy in FTLD patients substantially 
exceeded the amount of both in AD patients. The opposite pattern was observed for 
hypometabolism. Because both groups of dementia patients had a similar mild to moderate 
stage of dementia, these results indicate a differential development of both dementia types 
regarding the underlying mechanisms. In AD, at least at this early stage of dementia, the 
hypometabolism seems to be the predominating factor, while atrophy is less pronounced in this 
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group of patients. This observation indicates that changes in glucose metabolism, which is 
strongly connected to glutamatergic neuronal activity (Sibson et al., 1998), precede or have at 
least a faster mechanism in AD. The atrophy in this disease seems to be a slower process 
following the reduction of glucose in cortical structures. This assumption is consistent with 
research reporting beta amyloid, a histological feature in AD (Sisodia et al., 1990), to impair 
glucose transport in cortical and hippocampal neurons and in this way to contribute to neuronal 
degeneration in AD (Mark et al., 1997).  
FTLD patients show an inverse pattern of atrophy and hypometabolism in comparison to AD 
patients. In this group, GM atrophy substantially exceeds the reduction of glucose metabolism in 
most cortical and in all subcortical structures. Furthermore, WM atrophy is much more 
pronounced in this group. These results suggest a different process not primarily affecting 
glucose consumption to explain neurodegeneration in FTLD. Extended WM atrophy also 
indicates a mechanism that is not restricted to GM structures, which might be supportive of the 
recently reported results of TAR DNA-binding protein (DNA: deoxyribonucleic acid), TDP-43, to 
be the major disease protein in FTLD (Davidson et al., 2007). This protein has been reported to 
be not only restricted to GM structures in FTLD patients but also present in frontal and temporal 
WM structures and brainstem (Neumann et al., 2007), which is consistent with our results of 
WM intensity reductions in these regions. 
 
3.4.2. Support vector machine results 
As shown above, VBM using different imaging modalities might provide a helpful instrument to 
understand the underlying mechanisms of different types of dementia. However, it is also very 
important to use this information to improve not only the understanding but also the detection 
and differentiation of dementia. SVM classification is a very promising tool for these purposes, 
as has been shown by previous studies (Klöppel et al., 2008a; Davatzikos et al., 2008; Fan et 
al., 2008; Chaves et al., 2009). It not only captures univariate relationships of a single voxel 
across all subjects but is also able to detect multivariate relationships over a large group of 
information, as, for example, between different structures and modalities in the brain. 
Furthermore, this tool provides an easy way to use this information for classifying imaging data 
of new subjects to a specific condition.  
45 
 
Here, we systematically compared different information provided by FDG-PET and MRI to 
enable the most accurate detection and differentiation of dementia. Although the diagnoses of 
our subjects were not histopathologically confirmed to be sure of assigning them to the correct 
condition, generally higher conformity with the clinical diagnosis, which was based on 
comprehensive clinical and neuropsychological testing, should also result in more accurate 
classification of histopathologically validated data.  
The whole-brain SVM classification provided the most accurate classification using only FDG-
PET information. GM and WM based classification accuracy was lower for all comparisons 
indicating a lower sensitivity for detection of dementia-relevant information. Nonetheless, 
classification based on GM, WM and FDG-PET separately or combining them revealed a 
discrimination accuracy which was above chance level for the correct categorization of the three 
groups. All classification results substantially exceeded the best classification accuracy obtained 
by randomly assigning all subjects to different groups. Additionally, smoothing of the data 
improved the classification accuracy in both imaging modalities as expected. However, in 
whole-brain classification noise is introduced by using a great deal of information for 
classification that does not differentiate between the groups. Recent comprehensive meta-
analyses identified the “prototypical” networks for both disorders in both modalities using VBM 
(Schroeter et al., 2007, 2009). The involved regions have been shown to be affected in AD and 
FTLD patients most consistently in all studies investigating these disorders. By using this 
information, we ruled out the possibility that our classification results are dependent to our group 
of patients. Although this method provides lower accuracy rates for GM or FDG-PET information 
on their own, it shows a significantly higher discrimination rate by combining both information 
modalities into a single vector. This ROI-based discrimination is superior to whole-brain 
classification with the highest accuracy gain for the differentiation of both types of dementia, 
which, with 94%, is the highest differentiation rate reported up to now. Accordingly, we suggest 
this method as a diagnostic standard for the classification of dementia syndromes. 
 
3.4.3. Conclusion and perspectives 
In our study, we investigated the advantages of multimodal imaging using FDG-PET and MRI to 
improve understanding, detection and differentiation of dementia. AD and FTLD patients 
revealed a differential pattern of atrophy and hypometabolism, indicating different proceeding of 
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both disorders and providing support for the assumption of different underlying mechanisms in 
AD and FTLD. Furthermore, based on affected regions reported in previous studies, 
investigating AD and FTLD with univariate approaches and summarized in two meta-analyses, 
we applied linear SVM classification algorithm using information from both imaging modalities. 
Combining ROI information from FDG-PET and MRI resulted in a substantial gain in accuracy 
compared to whole-brain and to single modality classification for both detection and 
differentiation of AD and FTLD. Our results indicate that integration and combination of results 
from different imaging modalities might provide a new way to improve the understanding and 
diagnostic accuracy of these dementia disorders.  
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4. Validation of the support vector machine approach 
 
In the previous section it has been shown that combining ROI information from FDG-PET and 
structural MRI might substantially improve diagnostic accuracy of two common types of 
dementia, AD and FTLD. However, as the groups used in that study were recruited from a 
single clinical center, the results might be less generalizable to other clinical data. The following 
section deals with the validation of the proposed multimodal approach using data from different 
clinical centers.  
4.1. Introduction 
 
In recent research, studies investigating the use of biomarkers to improve diagnostic accuracy 
of dementia have become more and more frequent with most of them having a focus on 
optimizing the use of one specific biomarker or on the comparison of different biomarkers 
regarding their sensitivity for specific dementia syndromes (Fung and Stoeckel, 2007; 
Davatzikos et al., 2008; Habeck et al., 2008; Klöppel et al., 2008a; Chaves et al., 2009; Habert 
et al., 2009; Horn et al., 2009). However, frequently used statistical methods such as 
multivariate pattern classification with SVM do not only enable automatic classification using 
one specific biomarker but, as has been shown before, also provide a tool to combine two or 
more different biomarkers within the same classification model.  
The ROI approach described previously, although, less sensitive compared to whole-brain 
classification when using a single modality, was far superior to whole-brain classification when 
combined information from FDG-PET and MRI was used. Because ROIs for SVM were 
extracted from two comprehensive meta-analyses investigating both dementia syndromes 
(Schroeter et al., 2007, 2009) they were not biased to a specific dataset. Furthermore, the 
preprocessing algorithm suggested in this study was designed to overcome difficulties which 
might occur due to use of different scanner types and scanning sequences with different scaling 
and resolution. 
To validate and to investigate the generalizability of this approach, we applied same 
preprocessing and classification algorithm to two different datasets. Classification accuracy 
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results using FDG-PET and MRI data from the Day Clinic of Cognitive Neurology at the 
University of Leipzig were compared to classification results obtained using the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) database (www.adni-info.org). ADNI is a free access 
database containing FDG-PET and MRI data beside comprehensive neuropsychological and 
clinical evaluation of AD patients and healthy control subjects. 
 
4.2. Methods 
 
4.2.1. Day Clinic database 
Table 4.1 Subject group characteristics 
 Day Clinic group ADNI group 
 Controls AD Controls AD 
Number 13 21 28 28 
Male/Female 7/6 9/12 20/8 19/9 
Age (years) 53.9±6.0 61.1±6.7* 75.4±4.6~ 75.8±7.2~ 
CDR (score) 0.23±0.26 0.71±0.25* 0.02±0.09~ 0.80±0.25* 
Mean ± standard deviation. *significant difference to the control group from the same dataset, ~significant 
difference to the same diagnostic classification group from the Day Clinic dataset. AD Alzheimer’s 
disease, ADNI Alzheimer’s Disease Neuroimaging Initiative, CDR Clinical Dementia Rating Scale. 
 
We analyzed FDG-PET and T1-weighted MRI data of 21 patients (Table 4.1) with an early stage 
of probable AD, 14 patients with an early stage of FTLD and 13 control subjects. Patients were 
recruited from the Day Clinic of Cognitive Neurology at the University of Leipzig. Probable AD 
was diagnosed according to the original and revised NINCDS-ADRDA criteria (McKhann et al., 
1984; Dubois et al., 2007). Diagnosis of FTLD was based on criteria suggested by Neary et al. 
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(1998). The control group included subjects who visited the Day Clinic with subjective cognitive 
complaints, which were not objectively confirmed by a comprehensive neuropsychological and 
clinical evaluation. FDG-PET and MRI for these subjects was conducted within the clinical 
assessment for diagnostic reasons. This control group was chosen because, in clinical practice, 
it is crucial to discriminate between these subjects and patients with an early stage of dementia. 
Informed consent was obtained from all subjects. The research protocol was approved by the 
Ethics Committee of the University of Leipzig, and was in accordance with the latest version of 
the Declaration of Helsinki. 
 
4.2.2. Data acquisition 
a) Magnetic resonance imaging data 
For each subject, a high-resolution T1-weighted MRI scan was obtained, consisting of 128 
sagittal slices adjusted to AC-PC line and a with slice thickness of 1.5mm and pixel size of 
1×1mm². MRI was performed on two different 3T scanners (MedSpec 30/100, Bruker Biospin, 
Ettlingen Germany and Magnetom Trio, Siemens, Erlangen, Germany) using two different T1-
weighted sequences (MDEFT or MP-RAGE with TR=1300ms, TI=650ms, TE=3.93ms or 
TE=10ms; FOV 25×25 cm²; matrix = 256×256 voxels). On the MedSpec scanner, only the 
MDEFT-sequence and on the Magnetom Trio scanner, either MDEFT or MP-RAGE sequences 
were used.  
 
b) [F18]fluorodeoxyglucose positron emission tomography data 
Each subject also underwent FDG-PET imaging either a few a weeks before or after the MRI 
scan. All PET data were acquired on a Siemens ECAT EXACT HR+ scanner (CTI/Siemens, 
Knoxville, TN, USA) under a standard resting condition in 2-dimensional (2D) mode. The 2D 
acquisition mode was used because it allows a better quantification of the PET data due to 
lower scatter radiation. Sixty-three slices were simultaneously collected with an axial resolution 
of 5 mm full width at half maximum (FWHM) and in-plane resolution of 4.6 mm. After correction 
for attenuation, scatter, decay and scanner-specific dead-time, images were reconstructed by 
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filtered back-projection using a Hann-filter of 4.9 mm FWHM. The 63 transaxial slices obtained 
had a matrix of 128×128 voxels with an edge length of 2.45 mm. 
 
 
4.2.3. Alzheimer’s Disease Neuroimaging Initiative database 
a) Alzheimer’s Disease Neuroimaging Initiative subjects 
To validate the multimodal ROI-based classification approach proposed in chapter 3 and to 
make it more reliable and generalizable to multicenter data we extracted MR and FDG-PET 
images of 28 patients with Alzheimer’s disease and 28 healthy control subjects (Table 1) from 
the ADNI database. The ADNI is a partnership of the National Institute of Aging, the National 
Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private 
pharmaceutical companies and non-profit organizations. Diagnosis of AD patients was based on 
NINCDS/ARDRA criteria (McKhann et al., 1984). Exclusion criteria for the ADNI data were any 
significant neurological disease other than AD, history of head trauma followed by persistent 
neurological deficits or structural brain abnormalities, psychotic features, agitation or behavioral 
problems within the last three months or history of alcohol or substance abuse. For most 
subjects multiple follow-up FDG-PET and MR scans were available. To ensure that our 
approach is applicable for the early diagnosis of dementia for all subjects, data from the first 
FDG-PET and MR scan were used. 
 
b) Alzheimer’s Disease Neuroimaging Initiative magnetic resonance imaging data 
The MR dataset included standard T1-weighted images obtained with different scanner types 
using volumetric MPRAGE sequence varying in TR and TE with an in-plane resolution of 1.25 × 
1.25 mm and 1.2 mm sagittal slice thickness. Only images obtained using 1.5T scanners were 
used in this study. All images were preprocessed as described on the ADNI website 
(http://www.loni.ucla.edu/ADNI/Data/ADNI_Data.shtml), including distortion correction and B1 
non-uniformity correction. 
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c) Alzheimer’s Disease Neuroimaging Initiative [F18]fluorodeoxyglucose positron emission 
tomography data 
All ADNI subjects also underwent FDG-PET scanning obtained with different scanner types and 
using one of three different protocols: 1) dynamic: a 30 minute, six frame acquisition (6 five-
minute frames), with scanning from 30 to 60 min post-FDG injection;  2) static: a single-frame 30 
min acquisition with scanning 30-60 min post-injection; and 3) quantitative: a 60 min dynamic 
protocol consisting of 33 frames, with scanning beginning at injection and continuing for 60 min. 
The majority of the scans in the ADNI study were acquired with the first acquisition protocol. The 
images further differed in resolution, orientation, voxel and image dimensions and count 
statistics.  
 
4.2.4. Preprocessing of magnetic resonance and [F18]fluorodeoxyglucose positron emission 
tomography data 
For MR and FDG-PET data the same preprocessing procedure was applied as described in 
detail in chapter 3. This procedure (Figure 3.1) included interpolation of both FDG-PET and MR 
images to an isotropic resolution of 1×1×1 mm³, bias correction for inhomogenity artifacts for 
MR data, partial volume effect correction and masking of non GM voxels in FDG-PET data and 
spatial normalization to an averaged size template created from all subjects using the DARTEL 
approach (Ashburner, 2007).  The same deformations calculated based on the MR template 
were applied to MR and to co-registered FDG-PET images. After smoothing of FDG-PET and 
MR images with a Gaussian kernel of 12 mm FWHM, intensity normalization of FDG-PET data 
to cerebellum (Dukart et al., 2010) and subsequent masking, the procedure results in an 
accurate anatomical overlap of both modalities. Both imaging modalities then have the same 
spatial orientation, resolution and effective smoothness. Individual intensity normalization to the 
cerebellum also accounts for initially different count statistics of FDG-PET images. However, 
both imaging modalities are still in the DARTEL space. To extract regional values corresponding 
to ROIs reported in the meta-analyses investigating AD and FTLD (Schroeter et al., 2007, 2009) 
all images were normalized to the MNI template using affine-only transformation.  
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a) Region-of-interest extraction 
ROI coordinates were extracted using the MRIcron 3D fill tool 
(http://www.sph.sc.edu/comd/rorden/mricron) as described in chapter 3 from two 
comprehensive, systematic and quantitative meta-analyses investigating biomarkers of AD and 
FTLD in MR and FDG-PET images. Although the data extracted from the ADNI data base did 
not include FTLD patients, ROIs reported for this group of patients were also included in the 
classification procedure. The inclusion of these regions not only improves the differentiation 
between both dementia types but also improves the differentiation of AD patients and healthy 
control subjects providing rather less affected reference regions for the multivariate pattern 
classification and so improving the classification. The meta-analyses included a total number of 
1618 patients (AD/FTLD: 1351/267) and 1448 healthy control subjects (1097/351) (Schroeter et 
al., 2007, 2009). These meta-analyses extracted the prototypical networks of AD and FTLD by 
applying what is currently the most sophisticated and best-validated of coordinate-based voxel-
wise meta-analyses, the anatomical likelihood estimate. In the FTLD meta-analyses (Schroeter 
et al., 2007), only coordinates which are common to all subgroups of FTLD patients were used. 
Because the coordinates in both meta-analyses were reported in the Talairach space, they were 
transformed to MNI space according to a formula proposed by Matthew Brett (published on the 
Internet: http://www.mrccbu.cam.ac.uk/Imaging/Common/mnispace.shtml).  
 
b) Support vector machine classification 
Multivariate pattern classification was performed with a linear kernel by identifying a separating 
linear hyperplane that maximizes the distance between different clinical groups based on ROI 
information. Additionally, the cost parameter for incorrect classification was optimized for each 
dataset. The cross-validation of the trained SVM was performed by using the leave-one-out 
method. The procedure iteratively leaves out the information of each subject and trains the 
model on the remaining subjects for subsequent class assignation of the person that was not 
included in the training procedure. This validation method enables the generalization of the 
trained SVM to data that have never been presented to the SVM algorithms previously. The 
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reported accuracy is the percentage of subjects correctly assigned to the clinical diagnosis. To 
improve the validity of this approach, separate classifiers were trained based on the dataset 
from the ADNI database, the dataset of AD patients and control subjects from the Day Clinic of 
Cognitive Neurology or on combined data from both samples. Leaving-one-out cross-validation 
was performed for all classifiers. Furthermore, both classifiers trained separately only on one of 
both datasets were applied to the data not used for the training. SVM classification was applied 
separately to ROIs extracted from FDG-PET and MR data and to combined information from 
both imaging modalities.  
 
4.2.5. Statistical analysis 
Group comparisons for age and CDR (Clinical Dementia Rating Scale, Morris, 1993) were 
performed by conducting Bonferroni t-tests with a significance threshold of p<.05. Group 
differences regarding sex were evaluated using a chi-square test for independent samples. The 
statistical analysis was performed with the commercial software package SPSS 17.0 
(http://www.spss.com/statistics/).  
 
4.3. Results 
 
4.3.1. Clinical characteristics 
The chi-square test for independent samples did not reveal any statistical differences in sex 
between AD and Controls in the ADNI [χ²(1)=0.08;p=0.771] or in the Day Clinic dataset 
[χ²(1)=0.39;p=0.53. There was also no significant difference in sex between corresponding 
groups from both datasets, namely AD patients from the ADNI and the Day Clinic database 
[χ²(1)=3.06;p=0.08] and control subjects from the ADNI and the Day Clinic database 
[χ²(1)=1.22;p=0.27]).  
CDR scores differed significantly between AD patients and control subjects in the ADNI 
[t(54)=15.63;p<0.001] and in the Day Clinic dataset  [t(32)=5.36;p<0.001] but not between both 
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groups of AD patients [t(47)=1.23;p<0.22]. The control group from the Day Clinic had slightly but 
significantly higher CDR scores in comparison to the control group from the ADNI database 
[t(39)=3.87;p<0.001]. Age was substantially different between both datasets, with ADNI patients 
[t(47)=7.27;p<0.001] and control subjects [t(39)=12.59; p<0.001] being older than the 
corresponding group from the Day Clinic. There was a minor but significant difference between 
AD patients and control subjects in the Day Clinic group [t(32)=3.18;p=.008] but not in the ADNI 
dataset [t(54)=0.22;p=.83]. 
 
4.3.2. Support vector machine results 
Table 4.2  Accuracy rates for ROI-based SVM classification for FDG-PET and MRI separately 
and for combined information 
 FDG-PET MRI FDG-PET / MRI 
ADNI dataset 71.4% 66.1% 85.7% 
Day Clinic dataset 94.1% 82.4% 100.0% 
Combined dataset 87.8% 75.6% 91.1% 
therefrom ADNI 83.9% 73.2% 85.7% 
therefrom Day Clinic 94.1% 79.4% 100% 
Accuracy represents the percentage of subjects correctly assigned to the correct condition. AD 
Alzheimer’s disease, ADNI Alzheimer’s Disease Neuroimaging Initiative, FDG-PET 
[18F]fluorodeoxyglucose positron emission tomography, MRI magnetic resonance imaging, ROI region-
of-interest, SVM support vector machine. 
 
The differentiation accuracy for single modality classification using leaving-one-out cross-
validation was highest with 94% using FDG-PET ROI information in the Day Clinic dataset 
(Table 4.2). Lowest accuracy, with 66% was obtained using MR ROI information from the ADNI 
database. Classification accuracy using FDG-PET information was far superior to MR-based 
classification in all conditions. For all comparisons, the best classification accuracy was 
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obtained using combined regional information from FDG-PET and MR images. For these 
combined information accuracy rates ranged between 86 and 100%, with lowest accuracy using 
only the ADNI dataset and highest accuracy using the Day Clinic dataset. The overall accuracy 
for the combined dataset using both modalities was 91%, with sensitivity and specificity of 86% 
for subjects from the ADNI database and 100% sensitivity and specificity for data from the Day 
Clinic (Table 4.3). The prediction for Day Clinic patients using the ADNI dataset for training was 
very high with 91%. The opposite comparison revealed a prediction accuracy of 84%. 
 
Table 4.3  Differentiation rates for combined ROI information from FDG-PET and MRI 
 Accuracy Sensitivity Specificity 
ADNI dataset 85.7% 82.1% 89.3% 
Day Clinic dataset 100.0% 100.0% 100.0% 
Combined dataset 91.1% 91.8% 90.2% 
ADNI Alzheimer’s Disease Neuroimaging Initiative, FDG-PET [18F]fluorodeoxyglucose positron emission 
tomography, MRI magnetic resonance imaging, ROI region-of-interest. 
 
4.4. Discussion 
 
Recently, it has been shown that applying multivariate statistical methods on imaging markers 
might provide a substantial gain in accuracy for early detection and differentiation of dementia 
syndromes (Fung and Stoeckel, 2007; Davatzikos et al., 2008; Klöppel et al., 2008a; Chaves et 
al., 2009). However, although all studies applying multivariate statistical methods to improve 
diagnostic procedure have shown high detection and differentiation rates for different dementia 
syndromes, some of these increased accuracy rates have been obtained with a trade-off in 
generalizability of the proposed approaches to new datasets. This is the case because the 
number of features used to obtain high classification accuracy was determined by feature 
selection methods identifying a minimal number of regions that provide optimal separation 
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between different groups within the specific dataset and by using the same dataset to validate 
this approach (Fung and Stoeckel, 2007; Fan et al., 2008; Davatzikos et al., 2008; Gerardin et 
al., 2009). This method, although providing optimal classification accuracy in a specific sample, 
does not necessarily provide optimal classification for data from other clinical centers.  
The number of selected features using this approach might be specific to the clinical group used 
in the study and depended on the accuracy of the clinical diagnosis in the specific clinical center. 
Therefore, in clinical practice, to make the diagnostic procedure more generalizable, 
comparable and applicable to different clinical centers, the number of features used for 
classification should be stable and not dependent on a specific sample.  
A good alternative to this procedure is the approach applied by Klöppel et al., (2008a), namely 
using whole-brain information for the classification of dementia syndromes. This procedure is 
not biased to a specific feature selection and provides high discrimination accuracy for different 
dementia syndromes. A rather practical disadvantage of this method is the large number of 
features used for classification, which requires a large working memory and therefore specific 
hardware components, especially if more than one imaging modality is used for classification.  
Combining information from different imaging modalities which have been reported to be 
sensitive biomarkers for a specific neurodegenerative disorder substantially improves detection 
and differentiation of dementia in comparison to single modality approaches as has been shown 
in chapter 3. However, this improvement combining multimodal information was only observed if 
ROIs information were used but not using whole-brain information from FDG-PET and MRI. The 
ROI approach proposed in this study is not biased to a specific dataset because ROIs were 
extracted from two comprehensive meta-analyses investigating AD and FTLD, which included a 
large number of patients from different clinical centers (Schroeter et al., 2007, 2009). The 
results of our study indicate that this ROI approach is applicable to new datasets and is not 
dependent on specific scanner types or sequences. The combination of ROI information from 
FDG-PET and MRI was far superior to the single-modality ROI-based classification for all 
comparisons. Furthermore, our study indicates that classifiers trained on data provided by ADNI, 
which is an open access database, result in good discrimination accuracy for new data from a 
single clinical center and so even increase the potential applicability of the proposed approach 
in the clinical environment. Best discrimination accuracy with sensitivity and specificity of about 
90% was obtained for both datasets when the classifier was trained on the combined group 
consisting of all subjects.  
57 
 
 
4.4.1 Conclusion and perspectives 
In this study, we investigated the applicability of the approach proposed in chapter 3 for 
detection and differentiation of dementia syndromes using multimodal information to data from 
different clinical centers. For this purpose we used data from the ADNI database. The results of 
this study are in line with the previous finding that combining FDG-PET and MRI information 
substantially improves detection of patients with early to moderate stages of AD. Furthermore, 
the method proposed in our study provides a possibility to use data from open access 
databases to improve clinical diagnosis of dementia in single clinical centers. Therefore, it has a 
high relevance for general clinical application. Additionally, our approach provides an easy 
method to integrate further biomarkers, if those will have been validated by future research, to 
improve clinical diagnosis of various dementia syndromes. 
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5. General discussion and outlook  
 
As has been shown in previous chapters, the combination of biomarkers using univariate and 
multivariate statistical approaches might provide a useful tool for the evaluation of imaging 
abnormalities in different dementia syndromes and the integration of these into diagnostic 
procedure. However, various methodical aspects in preprocessing of the data, like intensity 
normalization in FDG-PET, might substantially affect the statistical outcome and the 
interpretation of the results (Chapter 2). For many of these questions, further methodical studies 
are required to investigate and to optimize their contribution to the subsequent statistical 
evaluation. Therefore, addressing such questions is particularly important to improve the use 
and combination of different imaging modalities like FDG-PET and MRI in dementia research.  
 
5.1. Methodical aspects in preprocessing 
The present work addressed the question of optimizing intensity normalization for FDG-PET 
data. Comparison of two different intensity normalization procedures either to the cerebellum 
and to the cerebral global mean revealed differential effects of both approaches for detection 
and differentiation of AD and FTLD. While cerebellar normalization was superior in detection of 
differences between dementia patients and healthy controls, normalization to the cerebral global 
mean was much more sensitive for differences between both groups of dementia patients. 
These results suggest a differential application of both normalization methods depending on the 
diagnostic question. Additionally, this methodical comparison demonstrated that investigation of 
clinically important questions like the existence of glucose hypermetabolism in specific 
psychiatric disorders might be biased by the choice of preprocessing procedures applied to 
address these questions.  
Further methodical issues addressed in the present work dealt with the development of a new 
preprocessing algorithm to overcome difficulties resulting from the use of different scanner types 
and sequences within the same imaging modality and to enable the combination and common 
qualitative and quantitative evaluation of different imaging modalities.  
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Methods enabling a common evaluation of images obtained using different scanner types and 
sequences are a prerequisite for the use of data extracted from large datasets like the ADNI 
database to improve diagnostic accuracy in single clinical centers. Such datasets are usually 
collected using different scanner types and sequences. To use these data for diagnostic 
procedures by applying univariate or multivariate statistical approaches, it is necessary to 
overcome difficulties arising due to different resolution, measurement procedures and different 
intensity scaling in FDG-PET, for example. Only when these problems are solved can classifiers 
trained on such a database be optimally used to differentiate patients and control subjects or 
different groups of patients in single clinical centers.  
Methodical questions regarding optimized preprocessing are directed towards enabling a 
qualitative and quantitative interpretation and comparison of observed signal changes in 
different imaging modalities. In FDG-PET the signal targeted for measurement is glucose 
utilization. MRI aims to measure structural brain information and so provide an estimation of 
atrophy in demented patients. In clinical setting, these modalities are usually evaluated 
independently using substantially different preprocessing algorithms, which is highly problematic 
for combined evaluation of both modalities as explained in more detail below.  
When evaluation within a single modality is required, the preprocessing algorithm is expected to 
have a similar effect in all subgroups because all preprocessing steps are applied to all data in 
the same order. Although this is not always the case, this is one of the reasons why 
preprocessing algorithms are sometimes addressed to a lesser extent in clinical studies when 
comparing groups in a single modality. However, this differential preprocessing is an important 
problem for common evaluation of different imaging modalities because each single 
preprocessing step might have a substantial effect on the statistical outcome. In the worst case, 
differences observed in two different imaging modalities might be a result of the difference in the 
preprocessing of each modality and not related to the signal measured. For this reason, studies 
comparing two different imaging modalities should try to exclude effects of differential 
preprocessing as far as possible by making the procedure more comparable for both imaging 
modalities. Two good examples of such a common preprocessing of FDG-PET and MRI 
enabling qualitative evaluation of both imaging modalities in dementia patients are recently 
published studies by Chetelat et al. (2008) and Villain et al. (2008).  
To overcome difficulties described above which have arisen in the present work due to 
combined use of different imaging modalities and due to different scanner types and sequences, 
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a new preprocessing algorithm was developed and applied to the data (Figure 3.1). This 
algorithm enabled a common statistical evaluation and interpretation of FDG-PET and MRI in 
AD and FTLD, revealing a differential pattern in the ratio of glucose hypometabolism and 
atrophy in both groups of dementia patients. Moreover, although data extracted from the ADNI 
database substantially differed in various parameters like quality and resolution, high diagnostic 
accuracy was obtained using these data after preprocessing for differentiation of AD patients 
and healthy controls. Nonetheless, the algorithm applied here is still in need of optimization and 
improvement. Some specific questions regarding the effect of an additional spatial normalization 
of MRI and FDG-PET data and modulation of FDG-PET images have still to be evaluated. 
 
5.2. Voxel-based morphometry and support vector machine classification in dementia 
 
In recent research a number of studies have reported changes in dementia patients in different 
imaging modalities using VBM (Mummery et al., 2000; Rosen et al., 2002; Ishii et al., 2005; 
Chetelat et al., 2008; Kanda et al., 2008). This method has been shown to be a sensitive tool for 
detecting group differences between AD and FTLD patients and control subjects and between 
both groups of dementia patients in specific regions. Studies applying VBM have further 
demonstrated that reductions in glucose metabolism and atrophy might provide a good 
measurement of progression in AD, thus indicating that VBM might be used for the evaluation of 
potential therapeutic treatment (Alexander et al., 2002; Diehl-Schmid et al., 2005; Kinkingnehun 
et al., 2008). However, this application of VBM in dementia, although allowing a good 
description and visualization of regions affected in the brain, provides only limited information to 
improve our understanding of the underlying mechanisms in specific dementia syndromes.  
A further, more informative, application of VBM to study the underlying mechanisms in specific 
dementia syndromes might be the common evaluation of different imaging markers like FDG-
PET and MRI. Chetelat et al. (2008) showed that qualitatively glucose hypometabolism 
substantially exceeded atrophy in most affected regions in AD patients, suggesting the 
intervention of additional hypometabolism-inducing factors in this specific disorder. Such a 
factor might be disconnection and amyloid deposition, resulting in genuine functional 
perturbations ahead of actual atrophy (Chetelat et al., 2008). Furthermore, such a multimodal 
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combination might provide a more differentiative insight into the progression and understanding 
of specific processes in AD. For example, Villain et al. (2008) found that hippocampal atrophy is 
specifically related to cingulum bundle disruption, which is in turn highly correlated to 
hypometabolism of the posterior cingulate cortex but also of the middle cingulate gyrus, 
thalamus, mammillary bodies and parahippocampal gyrus. They interpreted these findings as 
supportive evidence for the hypothesis that glucose hypometabolism of the posterior cingulate 
cortex not only results from local neuropathological changes, but mostly reflects the distant 
effect of neuronal damage in the hippocampal formation. Such disorder-related changes gained 
by coevaluation of FDG-PET and MRI provide a better insight into the pathological mechanisms 
in dementia in comparison to single-modality evaluation. They might be used for the 
development of new models of specific dementia syndromes and, in this way, to develop 
treatment alternatives. 
In the present work, similar questions were addressed by common evaluation of FDG-PET and 
MRI using VBM (Chapter 3). The results of the study indicate the amount of glucose 
hypometabolism to be the predominating factor in AD, while atrophy is less pronounced in this 
group of patients. This observation is consistent with results described by Chetelat et al. (2007) 
and indicates that changes in glucose metabolism, which is strongly connected to glutamatergic 
neuronal activity (Sibson et al., 1998), precede or have at least a faster mechanism in AD. 
However, an inverse pattern of atrophy and hypometabolism was observed in FTLD in 
comparison to AD patients with atrophy substantially exceeding the reduction of glucose 
metabolism in most cortical and in all subcortical structures. Additionally, extensive WM intensity 
reductions were observed in patients with FTLD, mainly in frontal and temporal regions and in 
the brain stem. These results suggest a different process not primarily affecting glucose 
consumption to explain neurodegeneration in FTLD. Extended WM atrophy also indicates a 
mechanism that is not restricted to GM structures, which might be supportive of the recently 
reported results of the TAR DNA-binding protein, TDP-43, to be the major disease protein in 
FTLD (Davidson et al., 2007). This protein has been reported to be not only restricted to GM 
structures in FTLD patients but also present in frontal and temporal WM structures and the 
brainstem (Neumann et al., 2007), which is consistent with the reduced WM intensity in these 
regions. 
Although it is difficult to establish causal relationships between different imaging markers and 
neuronal processes, this common evaluation of specific imaging modalities might be used to 
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generate or to test specific hypotheses to improve our understanding of mechanisms and 
progression in different neurodegenerative disorders.  
A further application of VBM results is their use in improving diagnostic procedures in dementia. 
In the present work, SVM was applied to imaging features extracted from FDG-PET and MRI 
based on two comprehensive meta-analyses investigating AD and FTLD (Schroeter et al., 2007, 
2009). Both meta-analyses reported coordinates of regions showing the largest overlap 
obtained by activation likelihood estimate between different studies investigating these specific 
disorders using VBM. In this way, it is possible to integrate the results of different VBM studies 
to improve single case diagnosis of patients with specific dementia syndromes.  Applying SVM 
to combined information from FDG-PET and MRI extracted from both meta-analyses has been 
shown to be an effective method of improving diagnostic accuracy for detection and 
differentiation of AD and FTLD (Chapters 3 and 4). This approach was superior to the use of 
whole-brain and single modality information, especially for differentiation of AD and FTLD. 
Furthermore, a similarly high accuracy was obtained by applying this approach onto data 
extracted from the ADNI database. The classifier trained on this database provided high 
discrimination accuracy for subjects and patients from the Leipzig Day Clinic of Cognitive 
Neurology. The generalizability of such methods to single clinical centers without a lot of 
modifications is highly important to have a valid and easily applicable tool in clinical settings. 
The method proposed in this work seems to be a reliable tool for increasing the diagnostic 
accuracy of specific dementia syndromes. Furthermore, this SVM algorithm can be easily 
modified to integrate additional bio- and clinical markers if these have been shown to be 
sensitive and highly specific for a neurodegenerative disorder, for instance from cerebrospinal 
fluid analysis of beta-amyloid or tau proteins as suggested by Dubois et al. (2007). Additional 
integration of such markers should further improve detection and differentiation of specific 
dementia syndromes like AD and FTLD.  
A major problem for a good estimate of the accuracy rate obtained with the SVM approach 
applied in this work is the lack of pathological validation of patients with both types of dementia 
syndromes used in this study. This might be a problem as the clinical diagnosis of dementia has 
been shown to be a less sensitive instrument, especially in the differentiation of AD and FTLD.  
However, this approach has been validated using two different independent samples from 
various clinical centers. Additionally, high discrimination accuracy was obtained for both AD and 
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FTLD. These results indicate that this SVM method is a valid and reliable instrument for 
detection and differentiation of specific dementia syndromes.  
The results of the present work emphasize the high potential of combined evaluation of different 
imaging markers to improve understanding and diagnostic accuracy of various types of 
dementia. The application of the multimodal classification approach described above resulted in 
a very high accuracy for both, detection and differentiation of AD and FTLD and is therefore of 
major importance for clinical application. 
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Die Demenzproblematik hat in den letzten Jahrzehnten in unserer Gesellschaft immer mehr an 
Bedeutung gewonnen. Dies hängt größtenteils mit der weiterhin steigenden durchschnittlichen 
Lebenserwartung zusammen. Während in einer jüngeren Bevölkerung der Demenzdiagnose 
anteilsmäßig nur eine geringe Bedeutung zukommt, steigt ab einem Alter von 50 bis 60 Jahren 
die Anzahl der Neuerkrankungen mit dem zunehmenden Alter exponentiell an. Derzeit leiden 
alleine in Deutschland geschätzte 1.07 Millionen Menschen an einer moderaten bis schweren 
Form einer Demenzerkrankung (Ziegler und Doblhammer, 2009). Prognostisch soll dabei die 
Anzahl von Demenzpatienten weltweit von 25 Millionen im Jahr 2000 auf rund 114 Millionen im 
Jahr 2050 ansteigen (Wimo et al., 2003), was die besondere Problematik dieser 
Erkrankungsform für unsere Gesellschaft nochmals verdeutlicht. Die häufigste Erkrankungsform 
mit ca. 60% stellt dabei die Alzheimerdemenz dar, bei der in den Anfangsstadien insbesondere 
Gedächtnisdefizite im Vordergrund stehen, die jedoch auch mit anderen kognitiven 
Beeinträchtigungen einhergehen können (Fratiglioni et al., 1999; Dubois et al., 2007). Die 
zweithäufigste neurodegenerative Demenzform im Alter ist die frontotemporale lobäre 
Degeneration (Ratnavalli et al,. 2002; Rosso et al., 2003), die jedoch auf der Symptomebene 
ein weniger homogenes Muster aufweist. Bei dieser Erkrankung können in den Anfangsstadien 
Verhaltens- und Persönlichkeitsänderungen, Beeinträchtigung des semantischen 
Sprachverständnisses oder aphasische Defizite vom Broccatyp im Vordergrund stehen.  
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Aufgrund dieses heterogenen Musters wurde für diese Demenzform eine Aufgliederung in drei 
verschiedene Subtypen vorgeschlagen, für die in verschiedenen Bildgebungsmodalitäten 
distinkte Beeinträchtigungen neuronaler Netzwerke gezeigt werden konnten (Neary et al., 1998).  
Die Früherkennung und die Unterscheidung der Alzheimererkrankung und der frontotemporalen 
lobären Degeneration sind jedoch nicht immer so eindeutig. Gemessen an der Histopathologie 
als derzeitigem „Goldstandard“ werden für die Alzheimerdemenz Genauigkeiten der klinischen 
Diagnose von 65 bis 100% angegeben (Klatka et al., 1996; Petrovitch et al., 2001; Rascovsky et 
al., 2002). Für die frontotemporale Demenz schwanken die Genauigkeitsangaben, vor allem 
wegen der Schwierigkeit der Abgrenzung zur Alzheimererkrankung, jedoch nur zwischen 17 
und 85% (Rascovsky et al., 2002; Knopman et al., 2005; Mendez et al., 2007), was deutlich 
einer weiteren Verbesserung bedarf.  
In der neueren Forschung wurden für beide Erkrankungsformen in unterschiedlichen 
Bildgebungsmodalitäten distinkte Veränderungen berichtet (Rosen et al., 2002; Ishii et al., 2005; 
Nestor et al., 2005; Desgranges et al., 2007; Clark et al., 2008; Habeck et al., 2008; Jack et al., 
2008). Die Auswertung dieser kann zu einer Verbesserung des Verständnisses, des 
Fortschreitens, der Symptomatik und der Krankheitsmechanismen bei unterschiedlichen 
Demenzformen beitragen. Außerdem konnte gezeigt werden, dass die Hinzunahme von 
Bildgebungsinformationen unter Verwendung verschiedener Methoden zu einer Verbesserung 
der Detektion und der Differenzierung beider Demenzformen substantiell beitragen kann 
(Habeck et al., 2008; Klöppel et al., 2008a, b; Habert et al., 2009).  
Um eine optimale interindividuelle Bewertung und Vergleiche von Bildgebungsmarkern zu 
ermöglichen, müssen die Daten zuerst mit Hilfe komplexer Vorverarbeitungsmechanismen 
räumlich und skalenmäßig standardisiert werden. Da die einzelnen Vorverarbeitungsschritte 
jedoch einen massiven Einfluss auf das Ergebnis haben können, muss dieser Einfluss klar 
bestimmt sein, damit eine optimale Evaluation der Bildgebungsinformationen möglich wird.  
Ein solcher wichtiger Vorverarbeitungsschritt für die Auswertung von Glukoseutilizationsdaten, 
gemessen mit der [F18]fluorodeoxyglukose Positronenemissionstomographie (FDG-PET), ist 
die Intensitätsnormalisierung. Diese ermöglicht eine Skalierung von Daten relativiert an einer 
Referenzregion. Die Wahl dieser Referenzregion hat dabei einen starken Einfluss auf das 
statistische Ergebnis bei Gruppenvergleichen (Ishii et al., 2001; Yakushev et al., 2008; 
Yakushev et al., 2009). Allerdings gibt es bislang keinen Konsens, welche Region für die 
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Intensitätsnormalisierung wann verwendet werden sollte. In der vorliegenden Arbeit wurden die 
beiden in der Literatur am häufigsten angewendeten Normalisierungsprozeduren auf das 
Kleinhirn und auf den Gesamtgehirndurchschnitt im Hinblick auf die Differenzierung von 
Gesunden und Demenzpatienten und auf die Unterscheidung zwischen zwei verschiedenen 
Demenztypen verglichen. FDG-PET Daten von Patienten mit Alzheimer Demenz, Patienten mit 
frontotemporalen lobären Degeneration und von gesunden Kontrollpersonen wurden möglichst 
ähnlich vorverarbeitet und dann entweder auf den Kleinhirn- oder auf den 
Gesamtgehirndurchschnitt normalisiert. Anschließend wurden für die drei Gruppen paarweise 
Gruppenvergleiche für beide Normalisierungsprozeduren separat berechnet.  Als Maß für die 
Güte der verwendeten Normalisierung wurde die Menge der nach der jeweiligen 
Normalisierungsmethode detektierten Veränderungen genommen. Dieses Maß wurde 
verwendet, da es für die klinische Praxis wichtig ist, eine möglichst klare Unterscheidung 
zwischen gesund und krank oder zwischen verschiedenen Krankheitstypen treffen zu können. 
Der Vergleich zeigte einen differentiellen Effekt der beiden Normalisierungsprozeduren. 
Während nach der cerebellären Normalisierung mehr Unterschiede zwischen Kontrollpersonen 
und beiden Patientengruppen festgestellt werden konnten, war die cerebrale Normalisierung 
vorteilhafter für den Zwischendemenzgruppenvergleich. Da das Kleinhirn im Gegensatz zum 
Gesamtgehirndurchschnitt bei beiden Demenzgruppen relativ unbeeinträchtigt ist, bietet es eine 
genauere Referenzregion für den Vergleich mit gesunden Kontrollpersonen. Die 
Gesamtgehirnnormalisierung stellt dagegen für den Vergleich beider Patientengruppen eine 
bessere/stabilere Referenzregion dar, da der Gesamtgehirndurchschnitt bei beiden 
Patientengruppen vergleichsweise ähnlich reduziert ist und somit die regionalen Unterschiede 
zwischen den beiden Gruppen bei dieser Normalisierungsmethode stärker betont werden. 
Zusammenfassend scheint die cerebelläre Normalisierung vorteilhafter für die Detektion von 
demenziellen Erkrankungen zu sein, während die Gesamtgehirnnormalisierung sensibler für die 
regionalen Unterschiede ist, wenn es um eine Unterscheidung zwischen verschiedenen 
Demenztypen geht.  
Eine weitere Fragestellung der vorliegenden Arbeit bestand in der kombinierten Auswertung von 
FDG-PET und Magnetoresonanztomographie (MRT) Daten von Patienten mit Alzheimer 
Demenz oder der frontotemporalen lobären Degeneration.  Beide Gruppen wurden in beiden 
Modalitäten mit einer gesunden Kontrollgruppe verglichen. Um eine gemeinsame Interpretation 
der modalitätsspezifischen Ergebnisse beziehungsweise eine kombinierte Verwendung beider 
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Modalitäten zu ermöglichen, wurde der Vorverarbeitungsalgorithmus modifiziert. Die FDG-PET 
und MRT Daten wurden ähnlich skaliert, auf die gleiche Auflösung interpoliert, den gleichen 
räumlichen Transformationen unterzogen und auf einen ähnlichen Glättungsfaktor gebracht. Die 
Vorverarbeitung resultierte außerdem in einer sehr genauen räumlichen Registrierung zwischen 
den Probanden und ermöglichte somit eine voxelweise Auswertung der statistischen 
Unterschiede zwischen den Gruppen. Dermaßen vorverarbeitet wurden die beiden 
Demenzgruppen mit den Kontrollpersonen in beiden Bildgebungsmodalitäten verglichen.  
Der statistische Vergleich ergab ein differenzielles Muster der Ausprägung der Veränderungen 
für beide Demenzgruppen. Während bei den Patienten mit der Alzheimer Diagnose die 
Glukoseutilizationsreduktion in den meisten Regionen stärker ausgeprägt war, war die 
Intensitätsreduktion im strukturellen MRT, als Maß für Atrophie, räumlich weniger stark 
ausgedehnt. Ein deutlich umgekehrtes Muster ergab sich hingegen für Patienten mit der 
frontotemporalen lobären Degeneration. Bei diesen dominierte vor allem die Atrophie in den 
frontotemporalen Regionen. Die für die Atrophie korrigierte Glukoseutilizationsreduktion war 
dagegen relativ gering ausgeprägt.  
Die Unterschiedliche Ausprägung von Atrophie und Glukoseutilizationsreduktion in den beiden 
Demenzgruppen deutet auf einen unterschiedlichen neuronalen Mechanismus bei beiden 
Erkrankungen. Während bei der Alzheimerdemenz zuerst die Glukoseutilization beeinträchtigt 
zu sein scheint und der Atrophievorgang im Vergleich dazu langsamer verläuft, deuten die 
Ergebnisse darauf hin, dass bei der frontotemporalen Demenz die Atrophie im Vordergrund der 
Erkrankung steht.  
In den letzten Jahren konnte außerdem für beide Bildgebungsmodalitäten separat gezeigt 
werden, dass die Veränderungen, die in diesen für beide Demenztypen gefunden wurden, unter 
Verwendung multivariater statistischer Methoden durchaus einen hohen diagnostischen Wert in 
Bezug auf eine Früherkennung und Differenzierung von demenziellen Syndromen haben 
(Davatzikos et al., 2008; Fung et al., 2007; Fan et al., 2008; Chaves et al., 2009; Horn et al., 
2009). In diesen Studien wurde jedoch zumeist nur eine der Bildgebungsmodalitäten untersucht 
oder die Bildgebungsmodalitäten miteinander verglichen. Die multivariate Musterklassifikation, 
als eine Möglichkeit die Bildgebung diagnostisch zu nutzen, bietet allerdings den Vorteil, dass 
Informationen aus verschiedenen Modalitäten leicht miteinander kombiniert werden können. 
Dieses Vorgehen könnte zu einer zusätzlichen Steigerung der diagnostischen Genauigkeit der 
Erkennung und Unterscheidung von Demenztypen beitragen.  
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Aus diesem Grunde wurde die multivariate Musterklassifikation in dieser Arbeit systematisch auf 
die Informationen aus beiden Bildgebungsmodalitäten angewendet. Die Zuordnungsgenauigkeit 
basierend auf der Bildgebung wurde im Hinblick auf Übereinstimmung mit der klinischen 
Diagnose verglichen. Dabei wurde das Klassifikationsverfahren systematisch auf 
Gesamtgehirn- und regionale Informationen aus MRT und FDG-PET Daten separat und auf 
kombinierte Informationen aus beiden Modalitäten angewendet. Für die Extraktion der 
regionalen Informationen wurden Koordinaten aus Metaanalysen verwendet, die die beiden 
Demenztypen im Hinblick auf Veränderungen in beiden Bildgebungsmodalitäten untersucht 
hatten (Schroeter et al., 2007, 2009). Der Musterklassifikationsalgorithmus lieferte die höchsten 
Genauigkeitsraten sowohl für die Unterscheidung zu Kontrollpersonen als auch für die 
Unterscheidung zwischen Alzheimerdemenz und frontotemporaler lobärer Degeneration, wenn 
regionale Informationen aus FDG-PET und MRT gemeinsam verwendet wurden. Dieser Ansatz 
war sowohl der Verwendung von Gesamtgehirninformationen als auch der separaten 
Auswertung von FDG-PET und MRT deutlich überlegen. Um diesen Ansatz zu validieren 
wurden Daten von Alzheimerpatienten und Kontrollpersonen aus einer Onlinedatenbank 
(Alzheimer’s Disease Neuroimaging Initiative) extrahiert und der 
Musterklassifikationsalgorithmus unter Verwendung von regionalen Informationen auf diese 
angewendet.  
Die Ergebnisse bestätigen die hohe diagnostische Genauigkeit der Verwendung von regionalen 
Informationen aus FDG-PET und MRT Bildgebung. Desweiteren wurde dadurch gezeigt, dass 
der multimodale Klassifizierungsalgorithmus eine zentrumsübergreifende Verbesserung der 
Demenzdiagnostik ermöglicht. Dies ist insbesondere wichtig, da die ADNI Datenbank im 
Rahmen von klinischer Forschung frei zugänglich ist. Mit Hilfe der multivariate 
Musterklassifikation basierend auf den ADNI Daten könnte somit die diagnostische Genauigkeit 
in einzelnen klinischen Zentren deutlich gesteigert und standardisiert werden. Aus diesem 
Grund haben die in dieser Arbeit vorgestellten Ergebnisse eine hohe klinische Relevanz und 
das Potential die Diagnostik und Differentialdiagnostik demenzieller Syndrome im klinischen 
Umfeld substantiell zu verbessern. 
 
 
69 
 
7. References 
 
Alexander, G.E., Chen, K., Pietrini, P., Rapoport, S.I., Reiman, E.M., 2002. Longitudinal PET 
evaluation of cerebral metabolic decline in dementia: A potential outcome measure in 
Alzheimer's disease treatment studies. American Journal of Psychiatry 159, 738-745. 
Ashburner, J., 2007. A fast diffeomorphic image registration algorithm. Neuroimage 38, 95-113. 
Ashburner, J., Friston, K.J., 2005. Unified segmentation. Neuroimage 26, 839-851. 
Borghammer, P., Cumming, P., Aanerud, J., Gjedde, A., 2009. Artefactual subcortical 
hyperperfusion in PET studies normalized to global mean: lessons from Parkinson's disease. 
Neuroimage 45, 249-257. 
Braak, H., Braak, E., 1991. Neuropathological stageing of Alzheimer-related changes. Acta 
Neuropathol 82, 239-259. 
Buchert, R., Wilke, F., Chakrabarti, B., Martin, B., Brenner, W., Mester, J., Clausen, M., 2005. 
Adjusted scaling of FDG positron emission tomography images for statistical evaluation in 
patients with suspected Alzheimer's disease. J Neuroimaging 15, 348-355. 
Chang, C.C., Lin, C.J., 2001. LIBSVM : a library for support vector machines. Software available 
at http://www.csie.ntu.edu.tw/~cjlin/libsvm. 
Chaves, R., Ramirez, J., Gorriz, J.M., Lopez, M., Salas-Gonzalez, D., Alvarez, I., Segovia, F., 
2009. SVM-based computer-aided diagnosis of the Alzheimer's disease using t-test NMSE 
feature selection with feature correlation weighting. Neurosci Lett 461, 293-297. 
Chetelat, G., Desgranges, B., Landeau, B., Mezenge, F., Poline, J.B., de la Sayette, V., Viader, 
F., Eustache, F., Baron, J.C., 2008. Direct voxel-based comparison between grey matter 
hypometabolism and atrophy in Alzheimer's disease. Brain 131, 60-71. 
Clark, C.M., Davatzikos, C., Borthakur, A., Newberg, A., Leight, S., Lee, V.M., Trojanowski, J.Q., 
2008. Biomarkers for early detection of Alzheimer pathology. Neurosignals 16, 11-18. 
Davatzikos, C., Resnick, S.M., Wu, X., Parmpi, P., Clark, C.M., 2008. Individual patient 
diagnosis of AD and FTD via high-dimensional pattern classification of MRI. Neuroimage 41, 
1220-1227. 
70 
 
Davidson, Y., Kelley, T., Mackenzie, I.R., Pickering-Brown, S., Du Plessis, D., Neary, D., 
Snowden, J.S., Mann, D.M., 2007. Ubiquitinated pathological lesions in frontotemporal lobar 
degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol 113, 521-533. 
Del Sole, A., Clerici, F., Chiti, A., Lecchi, M., Mariani, C., Maggiore, L., Mosconi, L., Lucignani, 
G., 2008. Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild 
cognitive impairment: an FDG PET study. Eur J Nucl Med Mol Imaging 35, 1357-1366. 
Desgranges, B., Matuszewski, V., Piolino, P., Chetelat, G., Mezenge, F., Landeau, B., de la 
Sayette, V., Belliard, S., Eustache, F., 2007. Anatomical and functional alterations in 
semantic dementia: a voxel-based MRI and PET study. Neurobiol Aging 28, 1904-1913. 
Diehl, J., Grimmer, T., Drzezga, A., Riemenschneider, M., Forstl, H., Kurz, A., 2004. Cerebral 
metabolic patterns at early stages of frontotemporal dementia and semantic dementia. A PET 
study. Neurobiol Aging 25, 1051-1056. 
Diehl-Schmid, J., Grimmer, T., Drzezga, A., Bornschein, S., Riemenschneider, M., Forstl, H., 
Schwaiger, M., Kurz, A., 2007. Decline of cerebral glucose metabolism in frontotemporal 
dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging 28, 42-50. 
Doody, R.S., Geldmacher, D.S., Gordon, B., Perdomo, C.A., Pratt, R.D., 2001. Open-label, 
multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with 
Alzheimer disease. Arch Neurol 58, 427-433. 
Dubois, B., Feldman, H.H., Jacova, C., Dekosky, S.T., Barberger-Gateau, P., Cummings, J., 
Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., Meguro, K., O'Brien, J., Pasquier, F., 
Robert, P., Rossor, M., Salloway, S., Stern, Y., Visser, P.J., Scheltens, P., 2007. Research 
criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. 
Lancet Neurol 6, 734-746. 
Dukart, J., Mueller, K., Horstmann, A., Vogt, B., Frisch, S., Barthel, H., Becker, G., Moller, H.E., 
Villringer, A., Sabri, O., Schroeter, M.L., 2010. Differential effects of global and cerebellar 
normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage 
49, 1490-1495. 
Edison, P., Archer, H.A., Hinz, R., Hammers, A., Pavese, N., Tai, Y.F., Hotton, G., Cutler, D., 
Fox, N., Kennedy, A., Rossor, M., Brooks, D.J., 2007. Amyloid, hypometabolism, and 
71 
 
cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 68, 501-
508. 
Fan, Y., Resnick, S.M., Wu, X., Davatzikos, C., 2008. Structural and functional biomarkers of 
prodromal Alzheimer's disease: a high-dimensional pattern classification study. Neuroimage 
41, 277-285. 
Fratiglioni, L., De Ronchi, D., Aguero-Torres, H., 1999. Worldwide prevalence and incidence of 
dementia. Drugs Aging 15, 365-375. 
Fung, G., Stoeckel, J., 2007. SVM feature selection for classification of SPECT images of 
Alzheimer's disease using spatial information. Knowledge and Information Systems 11, 243-
258. 
Gerardin, E., Chetelat, G., Chupin, M., Cuingnet, R., Desgranges, B., Kim, H.S., Niethammer, 
M., Dubois, B., Lehericy, S., Garnero, L., Eustache, F., Colliot, O., 2009. Multidimensional 
classification of hippocampal shape features discriminates Alzheimer's disease and mild 
cognitive impairment from normal aging. Neuroimage 47, 1476-1486. 
Geyer, S., Schleicher, A., Zilles, K., 1999. Areas 3a, 3b, and 1 of human primary somatosensory 
cortex. Neuroimage 10, 63-83. 
Gislason, T.B., Sjogren, M., Larsson, L., Skoog, I., 2003. The prevalence of frontal variant 
frontotemporal dementia and the frontal lobe syndrome in a population based sample of 85 
year olds. J Neurol Neurosurg Psychiatry 74, 867-871. 
Habeck, C., Foster, N.L., Perneczky, R., Kurz, A., Alexopoulos, P., Koeppe, R.A., Drzezga, A., 
Stern, Y., 2008. Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease. 
Neuroimage 40, 1503-1515. 
Habert, M.O., Horn, J.F., Sarazin, M., Lotterie, J.A., Puel, M., Onen, F., Zanca, M., Portet, F., 
Touchon, J., Verny, M., Mahieux, F., Giron, A., Fertil, B., Dubois, B., 2009. Brain perfusion 
SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease 
among patients with mild cognitive impairment. Neurobiol Aging. 
72 
 
Hansen, R.A., Gartlehner, G., Webb, A.P., Morgan, L.C., Moore, C.G., Jonas, D.E., 2008. 
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of 
Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 3, 211-225. 
Herholz, K., Schopphoff, H., Schmidt, M., Mielke, R., Eschner, W., Scheidhauer, K., Schicha, H., 
Heiss, W.D., Ebmeier, K., 2002. Direct comparison of spatially normalized PET and SPECT 
scans in Alzheimer's disease. J Nucl Med 43, 21-26. 
Hodges, J.R., Davies, R.R., Xuereb, J.H., Casey, B., Broe, M., Bak, T.H., Kril, J.J., Halliday, 
G.M., 2004. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 56, 399-
406. 
Hoffman, J.M., Welsh-Bohmer, K.A., Hanson, M., Crain, B., Hulette, C., Earl, N., Coleman, R.E., 
2000. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 41, 
1920-1928. 
Horn, J.F., Habert, M.O., Kas, A., Malek, Z., Maksud, P., Lacomblez, L., Giron, A., Fertil, B., 
2009. Differential automatic diagnosis between Alzheimer's disease and frontotemporal 
dementia based on perfusion SPECT images. Artif Intell Med 47, 147-158. 
Ikeda, M., Shigenobu, K., Fukuhara, R., Hokoishi, K., Maki, N., Nebu, A., Komori, K., Tanabe, 
H., 2004. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal 
lobar degeneration patients. Dement Geriatr Cogn Disord 17, 117-121. 
Ishii, K., Sasaki, H., Kono, A.K., Miyamoto, N., Fukuda, T., Mori, E., 2005. Comparison of gray 
matter and metabolic reduction in mild Alzheimer's disease using FDG-PET and voxel-based 
morphometric MR studies. Eur J Nucl Med Mol Imaging 32, 959-963. 
Ishii, K., Sasaki, M., Kitagaki, H., Yamaji, S., Sakamoto, S., Matsuda, K., Mori, E., 1997. 
Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. J Nucl Med 38, 
925-928. 
Ishii, K., Willoch, F., Minoshima, S., Drzezga, A., Ficaro, E.P., Cross, D.J., Kuhl, D.E., 
Schwaiger, M., 2001. Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: 
validation of anatomic standardization for atrophied brains. J Nucl Med 42, 548-557. 
73 
 
Jack, C.R., Jr., Lowe, V.J., Senjem, M.L., Weigand, S.D., Kemp, B.J., Shiung, M.M., Knopman, 
D.S., Boeve, B.F., Klunk, W.E., Mathis, C.A., Petersen, R.C., 2008. 11C PiB and structural 
MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild 
cognitive impairment. Brain 131, 665-680. 
Jagust, W., Reed, B., Mungas, D., Ellis, W., Decarli, C., 2007. What does fluorodeoxyglucose 
PET imaging add to a clinical diagnosis of dementia? Neurology 69, 871-877. 
Jeong, Y., Cho, S.S., Park, J.M., Kang, S.J., Lee, J.S., Kang, E., Na, D.L., Kim, S.E., 2005. 18F-
FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. J Nucl Med 
46, 233-239. 
Kanda, T., Ishii, K., Uemura, T., Miyamoto, N., Yoshikawa, T., Kono, A.K., Mori, E., 2008. 
Comparison of grey matter and metabolic reductions in frontotemporal dementia using FDG-
PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging 35, 2227-2234. 
Kawachi, T., Ishii, K., Sakamoto, S., Sasaki, M., Mori, T., Yamashita, F., Matsuda, H., Mori, E., 
2006. Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild 
Alzheimer's disease. Eur J Nucl Med Mol Imaging 33, 801-809. 
Kinkingnehun, S., Sarazin, M., Lehericy, S., Guichart-Gomez, E., Hergueta, T., Dubois, B., 2008. 
VBM anticipates the rate of progression of Alzheimer disease: a 3-year longitudinal study. 
Neurology 70, 2201-2211. 
Kipps, C.M., Hodges, J.R., Fryer, T.D., Nestor, P.J., 2009. Combined magnetic resonance 
imaging and positron emission tomography brain imaging in behavioural variant 
frontotemporal degeneration: refining the clinical phenotype. Brain 132, 2566-2578. 
Klatka, L.A., Schiffer, R.B., Powers, J.M., Kazee, A.M., 1996. Incorrect diagnosis of Alzheimer's 
disease. A clinicopathologic study. Arch Neurol 53, 35-42. 
Kloppel, S., Stonnington, C.M., Chu, C., Draganski, B., Scahill, R.I., Rohrer, J.D., Fox, N.C., 
Jack, C.R., Jr., Ashburner, J., Frackowiak, R.S., 2008a. Automatic classification of MR scans 
in Alzheimer's disease. Brain 131, 681-689. 
Kloppel, S., Stonnington, C.M., Barnes, J., Chen, F., Chu, C., Good, C.D., Mader, I., Mitchell, 
L.A., Patel, A.C., Roberts, C.C., Fox, N.C., Jack, C.R., Jr., Ashburner, J., Frackowiak, R.S., 
74 
 
2008b. Accuracy of dementia diagnosis: a direct comparison between radiologists and a 
computerized method. Brain 131, 2969-2974. 
Knopman, D.S., Boeve, B.F., Parisi, J.E., Dickson, D.W., Smith, G.E., Ivnik, R.J., Josephs, K.A., 
Petersen, R.C., 2005. Antemortem diagnosis of frontotemporal lobar degeneration. Ann 
Neurol 57, 480-488. 
Kushner, M., Tobin, M., Alavi, A., Chawluk, J., Rosen, M., Fazekas, F., Alavi, J., Reivich, M., 
1987. Cerebellar glucose consumption in normal and pathologic states using fluorine-FDG 
and PET. J Nucl Med 28, 1667-1670. 
Lerch, J.P., Pruessner, J.C., Zijdenbos, A., Hampel, H., Teipel, S.J., Evans, A.C., 2005. Focal 
decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. 
Cereb Cortex 15, 995-1001. 
Mark, R.J., Pang, Z., Geddes, J.W., Uchida, K., Mattson, M.P., 1997. Amyloid beta-peptide 
impairs glucose transport in hippocampal and cortical neurons: involvement of membrane 
lipid peroxidation. J Neurosci 17, 1046-1054. 
Matsunari, I., Samuraki, M., Chen, W.P., Yanase, D., Takeda, N., Ono, K., Yoshita, M., Matsuda, 
H., Yamada, M., Kinuya, S., 2007. Comparison of 18F-FDG PET and optimized voxel-based 
morphometry for detection of Alzheimer's disease: aging effect on diagnostic performance. J 
Nucl Med 48, 1961-1970. 
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., 1984. Clinical 
diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the 
auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. 
Neurology 34, 939-944. 
Mendez, M.F., Shapira, J.S., McMurtray, A., Licht, E., Miller, B.L., 2007. Accuracy of the clinical 
evaluation for frontotemporal dementia. Arch Neurol 64, 830-835. 
Mielke, R., Pietrzyk, U., Jacobs, A., Fink, G.R., Ichimiya, A., Kessler, J., Herholz, K., Heiss, 
W.D., 1994. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: 
comparison of perfusion and metabolic pattern. Eur J Nucl Med 21, 1052-1060. 
75 
 
Minoshima, S., Frey, K.A., Foster, N.L., Kuhl, D.E., 1995. Preserved pontine glucose 
metabolism in Alzheimer disease: a reference region for functional brain image (PET) 
analysis. J Comput Assist Tomogr 19, 541-547. 
Morris, J.C., 1993. The Clinical Dementia Rating (CDR): current version and scoring rules. 
Neurology 43, 2412-2414. 
Mosconi, L., De Santi, S., Li, Y., Li, J., Zhan, J., Tsui, W.H., Boppana, M., Pupi, A., de Leon, 
M.J., 2006. Visual rating of medial temporal lobe metabolism in mild cognitive impairment 
and Alzheimer's disease using FDG-PET. Eur J Nucl Med Mol Imaging 33, 210-221. 
Mosconi, L., Perani, D., Sorbi, S., Herholz, K., Nacmias, B., Holthoff, V., Salmon, E., Baron, J.C., 
De Cristofaro, M.T., Padovani, A., Borroni, B., Franceschi, M., Bracco, L., Pupi, A., 2004. 
MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. 
Neurology 63, 2332-2340. 
Mosconi, L., Tsui, W.H., Herholz, K., Pupi, A., Drzezga, A., Lucignani, G., Reiman, E.M., 
Holthoff, V., Kalbe, E., Sorbi, S., Diehl-Schmid, J., Perneczky, R., Clerici, F., Caselli, R., 
Beuthien-Baumann, B., Kurz, A., Minoshima, S., de Leon, M.J., 2008. Multicenter 
standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and 
other dementias. J Nucl Med 49, 390-398. 
Muller-Gartner, H.W., Links, J.M., Prince, J.L., Bryan, R.N., McVeigh, E., Leal, J.P., Davatzikos, 
C., Frost, J.J., 1992. Measurement of radiotracer concentration in brain gray matter using 
positron emission tomography: MRI-based correction for partial volume effects. J Cereb 
Blood Flow Metab 12, 571-583. 
Mummery, C.J., Patterson, K., Price, C.J., Ashburner, J., Frackowiak, R.S., Hodges, J.R., 2000. 
A voxel-based morphometry study of semantic dementia: relationship between temporal lobe 
atrophy and semantic memory. Ann Neurol 47, 36-45. 
Neary, D., Snowden, J.S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., 
Kertesz, A., Robert, P.H., Albert, M., Boone, K., Miller, B.L., Cummings, J., Benson, D.F., 
1998. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. 
Neurology 51, 1546-1554. 
76 
 
Nestor, P.J., Fryer, T.D., Hodges, J.R., 2006. Declarative memory impairments in Alzheimer's 
disease and semantic dementia. Neuroimage 30, 1010-1020. 
Neumann, M., Kwong, L.K., Truax, A.C., Vanmassenhove, B., Kretzschmar, H.A., Van Deerlin, 
V.M., Clark, C.M., Grossman, M., Miller, B.L., Trojanowski, J.Q., Lee, V.M., 2007. TDP-43-
positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive 
inclusions. J Neuropathol Exp Neurol 66, 177-183. 
Newberg, A.B., Wang, J., Rao, H., Swanson, R.L., Wintering, N., Karp, J.S., Alavi, A., 
Greenberg, J.H., Detre, J.A., 2005. Concurrent CBF and CMRGlc changes during human 
brain activation by combined fMRI-PET scanning. Neuroimage 28, 500-506. 
Perry, R.J., Graham, A., Williams, G., Rosen, H., Erzinclioglu, S., Weiner, M., Miller, B., Hodges, 
J., 2006. Patterns of frontal lobe atrophy in frontotemporal dementia: a volumetric MRI study. 
Dement Geriatr Cogn Disord 22, 278-287. 
Petrovitch, H., White, L.R., Ross, G.W., Steinhorn, S.C., Li, C.Y., Masaki, K.H., Davis, D.G., 
Nelson, J., Hardman, J., Curb, J.D., Blanchette, P.L., Launer, L.J., Yano, K., Markesbery, 
W.R., 2001. Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a 
population-based study. Neurology 57, 226-234. 
Quarantelli, M., Berkouk, K., Prinster, A., Landeau, B., Svarer, C., Balkay, L., Alfano, B., 
Brunetti, A., Baron, J.C., Salvatore, M., 2004. Integrated software for the analysis of brain 
PET/SPECT studies with partial-volume-effect correction. J Nucl Med 45, 192-201. 
Querbes, O., Aubry, F., Pariente, J., Lotterie, J.A., Demonet, J.F., Duret, V., Puel, M., Berry, I., 
Fort, J.C., Celsis, P., 2009. Early diagnosis of Alzheimer's disease using cortical thickness: 
impact of cognitive reserve. Brain 132, 2036-2047. 
Rabinovici, G.D., Seeley, W.W., Kim, E.J., Gorno-Tempini, M.L., Rascovsky, K., Pagliaro, T.A., 
Allison, S.C., Halabi, C., Kramer, J.H., Johnson, J.K., Weiner, M.W., Forman, M.S., 
Trojanowski, J.Q., Dearmond, S.J., Miller, B.L., Rosen, H.J., 2007. Distinct MRI atrophy 
patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. Am J 
Alzheimers Dis Other Demen 22, 474-488. 
77 
 
Rascovsky, K., Salmon, D.P., Ho, G.J., Galasko, D., Peavy, G.M., Hansen, L.A., Thal, L.J., 
2002. Cognitive profiles differ in autopsy-confirmed frontotemporal dementia and AD. 
Neurology 58, 1801-1808. 
Ratnavalli, E., Brayne, C., Dawson, K., Hodges, J.R., 2002. The prevalence of frontotemporal 
dementia. Neurology 58, 1615-1621. 
Rosen, H.J., Gorno-Tempini, M.L., Goldman, W.P., Perry, R.J., Schuff, N., Weiner, M., Feiwell, 
R., Kramer, J.H., Miller, B.L., 2002. Patterns of brain atrophy in frontotemporal dementia and 
semantic dementia. Neurology 58, 198-208. 
Rosso, S.M., Donker Kaat, L., Baks, T., Joosse, M., de Koning, I., Pijnenburg, Y., de Jong, D., 
Dooijes, D., Kamphorst, W., Ravid, R., Niermeijer, M.F., Verheij, F., Kremer, H.P., Scheltens, 
P., van Duijn, C.M., Heutink, P., van Swieten, J.C., 2003. Frontotemporal dementia in The 
Netherlands: patient characteristics and prevalence estimates from a population-based study. 
Brain 126, 2016-2022. 
Rousset, O.G., Ma, Y., Evans, A.C., 1998. Correction for partial volume effects in PET: principle 
and validation. J Nucl Med 39, 904-911. 
Sabri, O., Kendziorra, K., Wolf, H., Gertz, H.J., Brust, P., 2008. Acetylcholine receptors in 
dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging 35 Suppl 1, S30-45. 
Sadeghi, N., Foster, N.L., Wang, A.Y., Minoshima, S., Lieberman, A.P., Tasdizen, T., 2008. 
Automatic classification of Alzheimer's disease vs. Frontotemporal dementia: A spatial 
decision tree approach with FDG-PET. 2008 Ieee International Symposium on Biomedical 
Imaging: From Nano to Macro, Vols 1-4, 408-411 
Sakamoto, S., Ishii, K., Sasaki, M., Hosaka, K., Mori, T., Matsui, M., Hirono, N., Mori, E., 2002. 
Differences in cerebral metabolic impairment between early and late onset types of 
Alzheimer's disease. J Neurol Sci 200, 27-32. 
Salmon, E., Collette, F., Degueldre, C., Lemaire, C., Franck, G., 2000. Voxel-based analysis of 
confounding effects of age and dementia severity on cerebral metabolism in Alzheimer's 
disease. Hum Brain Mapp 10, 39-48. 
78 
 
Samuraki, M., Matsunari, I., Chen, W.P., Yajima, K., Yanase, D., Fujikawa, A., Takeda, N., 
Nishimura, S., Matsuda, H., Yamada, M., 2007. Partial volume effect-corrected FDG PET 
and grey matter volume loss in patients with mild Alzheimer's disease. Eur J Nucl Med Mol 
Imaging 34, 1658-1669. 
Santens, P., De Bleecker, J., Goethals, P., Strijckmans, K., Lemahieu, I., Slegers, G., Dierckx, 
R., De Reuck, J., 2001. Differential regional cerebral uptake of (18)F-fluoro-2-deoxy-D-
glucose in Alzheimer's disease and frontotemporal dementia at initial diagnosis. Eur Neurol 
45, 19-27. 
Schroeter, M.L., Raczka, K., Neumann, J., von Cramon, D.Y., 2008. Neural networks in 
frontotemporal dementia – a meta-analysis. Neurobiol Aging 29, 418-426. 
Schroeter, M.L., Raczka, K., Neumann, J., Yves von Cramon, D., 2007. Towards a nosology for 
frontotemporal lobar degenerations-a meta-analysis involving 267 subjects. Neuroimage 36, 
497-510. 
Schroeter, M.L., Stein, T., Maslowski, N., Neumann, J., 2009. Neural correlates of Alzheimer's 
disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 
1351 patients. Neuroimage 47, 1196-1206. 
Sibson, N.R., Dhankhar, A., Mason, G.F., Rothman, D.L., Behar, K.L., Shulman, R.G., 1998. 
Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. 
Proc Natl Acad Sci U S A 95, 316-321. 
Sisodia, S.S., Koo, E.H., Beyreuther, K., Unterbeck, A., Price, D.L., 1990. Evidence That Beta-
Amyloid Protein in Alzheimers-Disease Is Not Derived by Normal Processing. Science 248, 
492-495. 
The Lund and Manchester Groups, 1994. Clinical and neuropathological criteria for 
frontotemporal dementia. J Neurol. Neurosurg Psychiatry 57, 416-418. 
van de Pol, L.A., Hensel, A., van der Flier, W.M., Visser, P.J., Pijnenburg, Y.A., Barkhof, F., 
Gertz, H.J., Scheltens, P., 2006. Hippocampal atrophy on MRI in frontotemporal lobar 
degeneration and Alzheimer's disease. J Neurol Neurosurg Psychiatry 77, 439-442. 
79 
 
Varma, A.R., Snowden, J.S., Lloyd, J.J., Talbot, P.R., Mann, D.M., Neary, D., 1999. Evaluation 
of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and 
frontotemporal dementia. J Neurol Neurosurg Psychiatry 66, 184-188. 
Villain, N., Desgranges, B., Viader, F., de la Sayette, V., Mezenge, F., Landeau, B., Baron, J.C., 
Eustache, F., Chetelat, G., 2008. Relationships between hippocampal atrophy, white matter 
disruption, and gray matter hypometabolism in Alzheimer's disease. Journal of Neuroscience 
28, 6174-6181. 
Walker, A.J., Meares, S., Sachdev, P.S., Brodaty, H., 2005. The differentiation of mild 
frontotemporal dementia from Alzheimer's disease and healthy aging by neuropsychological 
tests. Int Psychogeriatr 17, 57-68. 
White, L.E., Andrews, T.J., Hulette, C., Richards, A., Groelle, M., Paydarfar, J., Purves, D., 1997. 
Structure of the human sensorimotor system. I: Morphology and cytoarchitecture of the 
central sulcus. Cereb Cortex 7, 18-30. 
Whitwell, J.L., Josephs, K.A., Rossor, M.N., Stevens, J.M., Revesz, T., Holton, J.L., Al-Sarraj, S., 
Godbolt, A.K., Fox, N.C., Warren, J.D., 2005. Magnetic resonance imaging signatures of 
tissue pathology in frontotemporal dementia. Arch Neurol 62, 1402-1408. 
Wilcock, G.K., Lilienfeld, S., Gaens, E., 2000. Efficacy and safety of galantamine in patients with 
mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine 
International-1 Study Group. BMJ 321, 1445-1449. 
Wimo, A., Winblad, B., Aguero-Torres, H., von Strauss, E., 2003. The magnitude of dementia 
occurrence in the world. Alzheimer Dis Assoc Disord 17, 63-67. 
World Health Organization, 2001. The World health report: 2001: Mental Health: New 
Understanding, New Hope. WHO. 
Yakushev, I., Hammers, A., Fellgiebel, A., Schmidtmann, I., Scheurich, A., Buchholz, H.G., 
Peters, J., Bartenstein, P., Lieb, K., Schreckenberger, M., 2009. SPM-based count 
normalization provides excellent discrimination of mild Alzheimer's disease and amnestic 
mild cognitive impairment from healthy aging. Neuroimage 44, 43-50. 
80 
 
Yakushev, I., Landvogt, C., Buchholz, H.G., Fellgiebel, A., Hammers, A., Scheurich, A., 
Schmidtmann, I., Gerhard, A., Schreckenberger, M., Bartenstein, P., 2008. Choice of 
reference area in studies of Alzheimer's disease using positron emission tomography with 
fluorodeoxyglucose-F18. Psychiatry Res 164, 143-153. 
Ziegler, U., Doblhammer, G., 2009. Prävalenz und Inzidenz von Demenz in Deutschland – Eine 
Studie auf Basis von Daten der gesetzlichen Krankenversicherungen von 2002. Published 
online at http://www.rostockerzentrum.de/publikationen/rz_diskussionpap 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
 
Erklärung über die eigenständige Abfassung der Arbeit 
 
Hiermit erkläre ich, dass ich die vorliegende Arbeit selbständig und ohne unzulässige Hilfe oder 
Benutzung anderer als der angegebenen Hilfsmittel angefertigt habe. Ich versichere, dass Dritte 
von mir weder unmittelbar noch mittelbar geldwerte Leistungen für Arbeiten erhalten haben, die 
im Zusammenhang mit dem Inhalt der vorgelegten Dissertation stehen, und dass die vorgelegte 
Arbeit weder im Inland noch im Ausland in gleicher oder ähnlicher Form einer anderen 
Prüfungsbehörde zum Zweck einer Promotion oder eines anderen Prüfungsverfahrens 
vorgelegt wurde. Alles aus anderen Quellen und von anderen Personen übernommene Material, 
das in der Arbeit verwendet wurde oder auf das direkt Bezug genommen wird, wurde als 
solches kenntlich gemacht. Insbesondere wurden alle Personen genannt, die direkt an der 
Entstehung der vorliegenden Arbeit beteiligt waren. 
 
 
 
 
 
 
................................. ....................................  
Datum Unterschrift 
 
 
 
 
................................. ....................................  
Datum Unterschrift 
 
